

CURRICULUM VITAE

MICHAEL I. KOUKOURAKIS, MD

RADIATION ONCOLOGIST

**PROFESSOR OF MEDICINE
MEDICAL SCHOOL
DEMOCRITUS UNIVERSITY OF THRACE**

**HEAD
DEPARTMENT OF RADIOTHERAPY – ONCOLOGY /
RADIOBIOLOGY AND RADIOPATHOLOGY UNIT
UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS
ALEXANDROUPOLIS - GREECE**

2016

CONTENTS

1. **GENERAL INFORMATION (pp 2)**
2. **POST-GRADUATE EDUCATION AND CLINICAL TRAINING (pp 3)**
3. **CLINICAL EXPERIENCE (pp 4)**
4. **RESEARCH ACTIVITIES (pp 5-6)**
5. **TEACHING EXPERIENCE (pp 6)**
6. **SUPERVISOR OF PHD THESIS (pp 7)**
7. **SUPERVISOR OF MSc OR GRADUATION THESIS OF STUDENTS OF THE SCHOOL OF MOLECULAR BIOLOGY (pp 7-9)**
8. **MEMBER OF SCIENTIFIC SOCIETIES (pp 8)**
9. **LECTURES AS AN INVITED SPEAKER (pp 8-12)**
10. **ORGANIZATION OF INTERNATIONAL CONGRESSES (pp 12)**
11. **EDITORIAL BOARD OF JOURNALS (pp 12)**
12. **REVIEWER IN PEER REVIEW JOURNALS (pp 13)**
13. **REVIEWER OF INTERNATIONAL RESEARCH PROPOSALS (pp 13)**
14. **BOOKS AND CHAPTERS (pp15-16)**
15. **PUBLISHED STUDIES IN THE INTERNATIONAL LITERATURE (pp 17-47)**
16. **ABSTRACTS PRESENTED IN INTERNATIONAL CONGRESSES (pp 48-53)**

1. GENERAL INFORMATION

NAME	Michael
NAME OF FATHER	Ioannis
NAME OF MOTHER	Dionysia
NAME OF WIFE	Alexandra Giatromanolaki, MD (Professor of Pathology)
PLACE OF BIRTH	Nikaia Peiraios
DATE OF BIRTH	27-7-1962
NATIONALITY	Hellenic
ADDRESS (HOME)	M. Koutavou 30 Alexandroupolis 68100, Greece
ADDRESS (WORK)	Department of Radiotherapy and Oncology, University Hospital of Alexandroupolis, Dragana, Greece (PO BOX 12)
TELEPHONE /MOBILE	25513-51622 / 6932480808
FAX	25510-30349

UNDERGRADUATE STUDIES

Gymnasium/Lyceum, Heraklion, Crete, Graduation 1979, mark A+

Certificat de Langue Francaise (Institut Francais d'Athenes)

First Certificate in English (University of Cambridge)

Attestato di conoscenza di lingua Italiana (Istituto Italiano di cultura di Atene)

UNIVERSITY STUDIES

Medical Degree, University of Athens, 1986, Mark A

Liscence of Medical Practice : No 13406- 19/8/1986

MILITARY SERVICE

Doctor Responsible for the 7th MOMA Mobile Reserve 1991

2. POST-GRADUATE EDUCATION AND CLINICAL TRAINING

1. 1/10/1986 - 9/7/1991

Title : *"Diplome d'Universite: Certificat d'etudes approfondies (CEA) de Cancerologie Clinique"*

University of Paris VII, France (Faculte de Medecine, Lariboisiere Saint Louis).

Thesis : "Les associations radio-chimiotherapie. Application de protocol PURE aux cancers de l'oesophage"

Training in

- Chemotherapy combination with radiation.
- Brachytherapy
- Whole body irradiation

2. 27/2/1987 - 27/2/1991

Title: Specialization in Radiation Oncology

(Hellenic Cancer Institute, Saint Savvas Hospital, Athens)

Training in

- Therapy decision making in the whole spectrum of oncology
- Radiotherapy Treatment Planning
- External beam irradiation (LINACs, KV irradiation, Betatron electron therapy)
- Intracavitary Brachytherapy for gynecological and nasopharyngeal malignancies
- Chemotherapy combinations
- In-patient care

3. 26/5/1992

Title: PhD in Medicine, University of Crete, Greece .

Thesis: "The role of CT-imaging in the planning of therapy for nasopharyngeal cancer"

4. 1/10/94 έως 1/10/1996

Post-doctoral studies in clinical trials at the ICRF Medical Oncology Unit, University of Oxford, UK
British Council Fellowship - "Honorary Senior Registrar , NHS Contract, Churchill Hospital, Oxford, UK

Training in

- Chemotherapy and Immunotherapy of cancer patients
- Writing and conduct of Phase I, II and III trials with novel chemotherapy agents
- Translational oncology studies in angiogenesis

3. CLINICAL EXPERIENCE

2. **1/12/1991- 25/8/1993**
 Honorary Senior Registrar, Department of Radiotherapy-Oncology, University Hospital of Heraklion, Crete, Greece
 - Leading position in the organization and running of the Department

3. **26/8/1993 till 1/10/95 and 1/10/96 till 21/10/1999,**
 Consultant, Department of Radiotherapy-Oncology, University Hospital of Heraklion, Crete, Greece
 - Treatment of 50% of cancer patients in the island of Crete
 - Organization of Radio-chemotherapy Unit

4. **1/10/94 till 1/10/1996**
 Post-doctoral studies in clinical trials at the ICRF Medical Oncology Unit, University of Oxford, UK, British Council Fellowship - "Honorary Senior Registrar , NHS Contract, Churchill Hospital, Oxford, UK
 Training in
 - Chemotherapy and Immunotherapy of cancer patients
 - Writing and conduct of Phase I, II and III trials with novel chemotherapy agents
 - Translational oncology studies in angiogenesis

5. **21/10/1999 till 3/9/2001,**
 Assistant Professor, Head, Department of Radiation Oncology, University of Thessaly, University Hospital of Larissa, Larissa, Greece.

4. **4/9/2001 till today,**
 - Assistant Professor (4-9-2001 to 9-6-2004), Associate Professor (10-6-2004 to 13/12/2009) and Chair (14/12/2009 to now), Medical School, Democritus University of Thrace
 - Director of the Department of Radiotherapy and Oncology
 - Full responsibility of the organization of the Department. Onset of treatment of patients 10/1/2003, (supervision of physicists for radiation protection and hazard reports, dosimetry of LINACs, Brachytherapy and Cobalt units and final license from the Hellenic Institute of Atomic Energy)
 - Development of Radio-chemotherapy and Chemotherapy Unit
 - The Department is the only cancer center in the North-East Greece and Thrace, treating 700 new patients per year (all type of tumors) and running the follow-up of all patients.
 - Development of a clinical and experimental radiobiology and radiopathology unit, aiming to develop novel radioprotection agents and radiation sensitizers
 - The department is member of the Multidisciplinary European Low Dose Initiative (MELODI) (<http://www.melodi-online.eu/partner.html>)

4. RESEARCH ACTIVITIES

- **Clinical Trials on altered fractionation and radio-chemotherapy**
 - Hypofractionated Accelerated RT for locally advanced tumors of the pelvis and head-neck area (Approval ΠΓΝΑ 73/10-2-2004, ΔΣ ΠΓΝΑ Σ.Δ.7° / 26-2-2004).
 - Conformal Hypofractionated Accelerated RT for the treatment of breast cancer (approval ΠΓΝΑ 322/23-6-2004, ΔΣ ΠΓΝΑ Σ.Δ.24° / 6-10-2004).
 - Phase II trial on the treatment of locally advanced gastric cancer with Lipoplatin, 5FU and Radiotherapy (ΕΟΦ Αα-ΚΔ-72/01/04, approval ΠΓΝΑ 284/10-7-2003, ΔΣ ΠΓΝΑ Σ.Δ.29° / 11-9-2003).
 - Preoperative and Radical Radiotherapy for inoperable locally advanced rectal cancer (approval ΠΓΝΑ 13/7/10-11-2005, ΔΣ ΠΓΝΑ Σ.Δ.25° / 8-12-2005)
 - Study of radiation induced fibrosis and pneumonitis after radiotherapy for locally advanced non-small cell lung cancer (approval ΠΓΝΑ 2/32/16-3-2006, ΔΣ ΠΓΝΑ Σ.Δ.43° / 30-3-2006)
 - Radical radio-chemotherapy for head-neck cancer combining inhibitors of EGFR (approval ΠΓΝΑ 15/7/12-9-2006, ΔΣ ΠΓΝΑ Σ.Δ.34° / 28-9-2006)
 - Study of body metabolism of patients undergoing radiotherapy (approval ΠΓΝΑ 9/4/4-7-2007, ΔΣ ΠΓΝΑ Σ.Δ.32° / 6-9-2007)

- **Translational research projects**
 - Research project funded by the University Special Account (code 81006, started 2012) under the title «Development of methods for the evaluation of the radiosensitivity of normal tissues ».
 - Study of the γ H2AX kinetics in peripheral PBMCs
 - Study of the γ H2AX kinetics in peripheral blood CD33 and CD14 stem cells, in vivo before and after the first fraction of radiotherapy
 - In collaboration with the CR UK, Molecular Oncology laboratory (Professor Adrian L. Harris) and with the Nuffield Department of Cellular Science (Professor Kevin C. Gatter). Research programmes funded by CR UK grants and the
 - ARISTEIA I / ESPA funding program 2007-2013 - GENERAL SECRETARIAT OF RESEARCH AND TECHNOLOGY. Title: TALK / 520 – “Targeting Autophago-Lysosomal Kinetics for the treatment of cancer and the prevention of anti-cancer therapy toxicities”
 - ARISTEIA II / ESPA funding program 2007-2013 - GENERAL SECRETARIAT OF RESEARCH AND TECHNOLOGY Title: MetaboliCA / 4046 – “Targeting tumour stroma and cancer cell metabolic co-operation for Lung Cancer Therapy”
 - Angiogenesis related markers and prognosis of cancer
 - Autophagy related markers and prognosis of cancer
 - Hypoxia and Metabolism molecules as cancer prognosis biomarkers and predictors of response to radiotherapy and chemotherapy
 - Angiogenesis, NOTCH signaling and resistance to radiotherapy
 - Development of nuclear imaging methods (RGD/avb3) for the in vivo detection of tumor angiogenic activity
 - In collaboration with the Department of Radiotherapy, MD ANDERSON CANCER CENTER, HOUSTON, USA (Prof. David Rosenthal) :
 - Evaluation of toxicity of radio-chemotherapy in patients with head-neck cancer using the MD Anderson Symptom Inventory – Head and Neck (MDASI-HN)
 - In collaboration with the clinical group that conducted the CONFIRM 1 και 2 randomized trials. Funded by Schering AG GERMANY and NOVARTIS AG USA :
 - Investigation of lactate dehydrogenase 5 expression and of other hypoxia and angiogenesis protein expression in colorectal cancer tissues and serum form patients recruited in the

randomized CONFIRM trials, investigating the therapeutic role of the VEGF pharmacological inhibitor PTK787/ZK222584 (EU and USA centres collaboration)

- Experimental Research project funded by JANSSEN PHARMACEUTICA NV, Belgium
 - Potential role of ARN-509, a compound targeting the hormone-refractory prostate cancer in the Radio-sensitization of prostate cancer

- **Basic Research studies**

- Autophagic Response of normal cells (fibroblasts and endothelium) and animal tissues after irradiation – Development of novel autophagy inducer molecules as cytoprotection strategies targeting autophagy
 - Glycolysis and Mitochondrial enzyme targeting, for the treatment of cancer
 - Radiation induced death pathways and kinetics
 - Effect if Hyperthermia and Hypothermia on death pathways and response to radiotherapy and chemotherapy
 - In vitro assessment of α/β cancer cell ratio values
 - Growth, metabolism and migration changes in cancer cell co-cultures with fibroblasts

5. TEACHING EXPERIENCE

Teaching of medical students in Universities

- **1991-93.** Contribution to the teaching of choice subject: «Radiobiology and Radioprotection», Medical School University of Crete, Greece.
- **1993-94.** Teaching of the subject ‘Radiation Protection’ in the School of Nurse, TEI, Heraklion, Crete Greece. Supervision of multiple diploma dissertations.
- **1999-2001.** As Assistant Professor. Responsible for the teaching of the subject of ‘Radiation Oncology’ (4th year of training) in the Medical School, University of Thessalia, Greece.
- **2002-2012.** As Assistant and Associate Professor. Responsible for the teaching of the choice subject of ‘Radiation Oncology’ (4th year of training) in the Medical School, Democritus University of Thrace, Greece.
- **2008-today.** As Associate Professor and Professor. Responsible for the teaching of the choice subject of ‘Exposure to ionizing radiation – Medical care’ (4th year of training) in the Medical School, Democritus University of Thrace, Greece.
- **2011-today.** As Professor. Responsible for the teaching of the core subject of ‘Oncology’ (4th year of training) in the Medical School, Democritus University of Thrace, Greece.

Teaching in Post-graduation courses

- **2004-2008.** Post-graduation specialization diploma (MSc) in hepatobiliary and pancreatic surgery, – Medical School, Democritus University of Thrace, Greece.
- **2005-2014.** Post-graduation specialization diploma (MSc) in Health care and work safety, Medical School, Democritus University of Thrace, Greece.
- **2006-2014.** Post-graduation specialization diploma (MSc) in Clinical Pharmacology – Medical School, Democritus University of Thrace, Greece.
- **2013-2014.** Post-graduation specialization diploma (MSc) in Nose surgery – Medical School, Democritus University of Thrace, Greece.

6. SUPERVISOR OF PhD THESIS

SUPERVISOR

Accomplished:

1. 2008: Changes of the immunophenotype of patients with head neck cancer undergoing radiotherapy
2. 2008: Autophagy cell adaptation during radiotherapy
3. 2009: Comparative study of different fractionation schemes for the treatment of bladder cancer
4. 2014: γ H2AX as biomarker for individual radiosensitivity

On going:

1. Photodynamic therapy and electrochemotherapy of cancer
2. Stem-like cancer cells in head neck cancer and response to radiotherapy
3. targeting Autophagy for the treatment of glioblastoma

SUPERVISING COMMITTEE

Accomplished:

1. 2001: The role of platelets in inflammatory bowel disease
2. 2006: Linear analysis of magneto-encephalographic signals from patients with Alzheimer disease
3. 2007: Angiogenesis and Hypoxia in gynecological cancer
4. 2008: Angiogenesis in the hyperplasia and adenoma development of the parathyroid glands
5. 2010: Molecular markers in breast cancer
6. 2013: Radiobiology effects of low dose irradiation of cancer cell lines
7. 2013: Autophagy and apoptosis in non-small cell lung cancer

On going:

1. Photodynamic therapy and electrochemotherapy of cancer
2. Combined androgen deprivation and hypofractionated radiotherapy for the treatment of prostate cancer
3. Salivary gland function during radiotherapy for head neck cancer

7. SUPERVISOR OF MSc or GRADUATION THESIS OF STUDENTS OF THE SCHOOL OF MOLECULAR BIOLOGY

1. Cytogenetic study of the activity of amifostine in patients undergoing radiotherapy (MSc in Clinical Pharmacology)
2. Molecular targets for radiosensitization (MSc in Clinical Pharmacology)
3. Cytogenetic study of camptothecins in combination with gamma radiation in human lymphocytes
4. The effect of exercise in physical parameter and quality of life in women with breast cancer
5. Autophagic response of intestinal epithelium following exposure of BALB/c mice to whole body irradiation
6. Effect of amifostine on glycolytic enzymes in the liver of BALB/c mice
7. The role of Pyruvate Dehydrogenase and its kinase in the sensitivity of glioblastoma cell lines
8. Autophagic response of glioblastoma cell lines following exposure to various stress factors
9. Lactate dehydrogenase A and B and sensitivity of glioblastoma cell lines
10. Effect of ionizing radiation in the expression of proteins involved in autophagy and lysosomal genesis in glioblastoma cell lines
11. Radiosensitization of glioblastoma cell lines using DCA
12. Metabolic characterization of glioblastoma cell lines under hypoxia
13. Study of the radiosensitizing effect of 2-deoxy-D-glucose in glioblastoma cell lines

14. Metabolic characterization of lung cancer cell lines
15. Lysosomal biogenesis and radiosensitization
16. Double metabolic inhibition (aerobic and anaerobic) using sodium oxamate and siPDH and radiosensitization in glioblastoma cell lines
17. In vitro assessment of the a/b ratio of lung cancer cell lines
18. Double metabolic inhibition with amiodarone and siLDHA and radiosensitization of glioblastoma cell lines

8. MEMBER OF SCIENTIFIC SOCIETIES

1. Hellenic Society for Radiation Oncology (Founding Member)
2. American Association for Cancer Research (A.A.C.R.).
3. American Society of Clinical Oncology (A.S.C.O.)
4. American Society for Therapeutic Radiology and Oncology (A.S.T.R.O.)
5. European Society for Therapeutic Radiology & Oncology (E.S.T.R.O.)
6. Multidisciplinary European Low Dose Initiative (MELODI)
7. Tumour and Angiogenesis Research Group (T.A.R.G) (Founding Member)
8. Hellenic Society for Hyperthermic Oncology (Founding Member)

9. LECTURES AS AN INVITED SPEAKER

A. International (32)

32. **9th International Conference of Anticancer Institute**
(co-ordinators: **R. Clarke, J. Holst**)
Sithonia, Greece. October 6- 10, 2014
Lecture : LC3A vs. LC3B: two distinct autophagosomal markers to consider for experimental and translational studies
31. **AROME educational course: Radiation and Cancer Biology.**
(co-ordinators: **Barry S. Rosenstein and Martin N. Pruschy**)
Istanbul, Turkey. May 27- 29, 2010
Lecture : Radioprotectants: from biology to clinical practice
30. **AROME educational course: Radiation and Cancer Biology.**
(co-ordinators: **Barry S. Rosenstein and Martin N. Pruschy**)
Istanbul, Turkey. May 27- 29, 2010
Lecture : Current and future molecular target agents for combined treatment modalities.
29. **3rd International Symposium on Primary Systemic Treatment in the Management of Operable Breast Cancer.**
Cremona, Italy. September 30th- October 2nd 2007
Co-ordinator: M. Aglieta, F Boccardo
Keynote Lecture : Tumour microenvironment and its relationship to the therapy
28. **5th International Congress on Lung Cancer**
Patra, January 24-27 , 2007
Co-ordinator: Siablis D, Andonadou D

- Lecture : The changing role of radiotherapy in lung cancer. The influence of new treatment modalities and combined treatments.
27. **PTK/ZK Consultancy Meeting. Analysing future colorectal cancer therapies.**
Paris, October 29, 2005
Co-ordinator: Dirk Laurent
Lecture : Lactate dehydrogenase, VEGF and human malignancies
 26. **3e Journe Romande de Radio-Oncologie**
Chavannes-de-Bogis, Switzerland, 25 May, 2005
Co-ordinator: Prof. M. Ozsahin
Lecture : Amifostine / IMRT in the treatment of Head and Neck Cancer
 25. **Radioprotecion in HNC**
University Hospital of Berne, Switzerland, 13 October, 2004
Co-ordinator: Prof. R. Greiner
Lecture : Amifostine and IMRT in the treatment of Head and Neck Cancer
 24. **Radioprotecion / Radiosensibilisation and IMRT.**
University Hospital of Zurich, Switzerland, 12 October, 2004
Co-ordinator: Prof. M. Lutolf
Lecture : Systemic approach for radioprotection
 23. **XII Congreso Asociacion Espanola de Radioterapia Oncologica. Symposium Satellite: Avances en citoproteccion.**
Las Palmas de Gran Canaria,, Spain, 8 October, 2003
Co-ordinator: Prof. M. Macia
Lecture : Amifostine selectivity and cytoprotective efficacy
 22. **Optimizing Radiation Therapy: Cytoprotection and Chemotherapy [European Cancer Conference ECCO12 official symposium].**
Copenhagen, Denmark, 21 September, 2003
Co-ordinator: Prof. Minesh Mehta
Lecture : New insights into the Biology of Amifostine: Clinical Relevance.
 21. **7th Biennial International Meeting. Angiogenesis: Basic Science and Clinical Applications**
Knossos Royal, Crete, Greece , 7 July, 2003
Co-ordinator: Prof. M Konerding
Lecture : Immunohistochemical markers of hypoxia/angiogenesis and radiotherapy outcome.
 20. **Ethylol cutaneous toxicity advisory panel (ECTAP)**
Marriott Westfields, Washington, USA , 9 December, 2002
Co-ordinator: Prof. Todd Wasserman
Lecture : Cutaneous necrolytic syndromes related to Ethylol
 19. **2nd International Congress on Cytoprotection**
St Thomas, US Virgin Islands, USA , 6-9 May, 2002
Co-ordinator: Prof. E. Curran (Chairman of the RTOG)
Lecture : Hypofractionated and Accelerated Radiotherapy with amifostine Cytoprotection (HypoARC). A new concept in radiotherapy and encouraging results in breast cancer.
 18. **Symposium: Novel Approaches in the Management of Solid tumors**
Barcelona, Spain, 1 March, 2002
Lecture : Amifostine: enhancing the efficacy of radiotherapy and of chemo-radiotherapy
 17. **Ethylol Meeting in South Africa**
Cape Town, South Africa, 13 June, 2001
Co-ordinator: Prof. E. Smit and Prof. D. Werner
Durban, South Africa, 14 June, 2001
Co-ordinator: Prof. JP Jordaan
Johanesburgh, South Africa, 15 June, 2001
Co-ordinator: Prof. R. Sur
Lecture: Ethylol in the clinical practice of radiotherapy and chemotherapy
 16. **Franco-Greek Exchange on 'Thoracic Oncology: Current and Future'.**
Athens, 29 June 2001

- Co-ordinator: Prof. A. Depierre
Lecture: Treatment of stage IIIb non-small cell lung cancer
15. **6th Biannual International Meeting on Angiogenesis: Basic Science and Clinical Developments.**
Crete, 26 June - 2 July 2001
Co-ordinator: Prof. Z. Hussain
Lecture: Assessment of VEGF/KDR activated angiogenic pathway in human cancer. Prognostic and therapeutic implications.
 14. **International Conference on 'Invasion and Metastasis'**
Kapandriti 14-17 June 2001
Co-ordinator: S. Kumar
Lecture: Targeting the VEGF/KDR angiogenic pathway
 13. **Postgraduate course in Neuropathology and Urological Pathology.**
Alexandroupolis, 11 October – 13 October, 2001
Co-ordinator: Prof. N. Agnantis
Lectures : a. Implications of Molecular Factors in the treatment of glioblastomas
b. Implications of Molecular Factors in the treatment of bladder cancer
 12. **Advances in Radiation Oncology**
Sattelite Symposium, ESTRO Congress 2000
Turkey, Istambul, 20 September, 2000
Co-ordinator: Prof. F. Eschwege
Lecture: Subcutaneous injection of Ethyol: the emerging role of Ethyol
 11. **Actualizacion en el cancer de cabeza y cuello avanzado.**
Spain, Santander , 5 May, 2000.
Co-ordinator: Dr. L.P dela Lastra
Lecture: Role of amifostine in chemoradiotherapy treatment
 10. **Novel approaches in the managment of solid tumors.**
Egypt, Sharm el Sheikh ,13-16 April, 2000.
Co-ordinator: Dr. F. El-Khatib, Dr. Z. Salem
Lecture: Amifostine during fractionated radiotherapy and chemo-radiotherapy: important role in the improvement of the therapeutic index
 9. **UK Head and Neck Group Oncology Meeting**
UK, Glasgow, 3 March, 2000
Co-ordinator: Dr. A.G Robertson
Lecture: Subcutaneous Amifostine
 8. **Tumours Angiogenesis : Implications in prognosis and treatment of cancer.**
Advanced course of the European School of Oncology
Advanced course of the European School of Oncology
Alexandroupolis 27-28 October, 2000
Co-ordinator: Prof. A. L. Harris
Lecture: Tumour angiogenesis and Radiotherapy
 7. **Angiogenesis: Molecular and Integrative Pharmacology,**
5th Biannual international conference on angiogenesis,
Greece, Crete, 1-7 July, 1999
Co-ordinator: Dr. Th. Fotsis
Lecture: Angiogenesis, thymidine phosphorylase and tumour remodelling during radiotherapy for head and neck cancer.
 6. **Drug targeting in cancer therapy,**
European School of Oncology course
Greece, Athens, 8-9 October 1999
Co-ordinator: Prof. M. Maragoudakis
Lecture: Quantitative aspects of angiogenesis in human tumors as basis for prognosis and guide to therapy
 5. **Radioprotection - Fighting head and neck cancer radiation toxicity**

European Congress of Clinical Oncology, ECCO10
Austria, Vienna, 12 September 1999.
Co-ordinator: Prof. F Eschwege, Dr. R. Sauer
Lecture: New route of Ethyol administration: subcutaneous usage

4. Local Therapy in conservatively treated breast cancer patients.

4th International Congress of HSBCR
Greece, Crete, 4-7 November, 1999.
Co-ordinator: Dr. A. Sotiropoulou
Lecture: Predictive factors of response to radiotherapy and chemotherapy

3. Cytoprotection in Cancer Therapy: Improving the Therapeutic Index of Cancer

Treatment. *ETHYOL Investigator Meeting*, American Society of Clinical Oncology
USA, Los Angeles, California, 16-19 May, 1998
Co-ordinator: Prof. C. Bokemeyer
Lecture: The use of Ethyol in chemotherapy and radiation therapy.

2. The prognostic value of biological factors in NSCLC.

3rd International Congress on Lung Cancer, Main Symposium.
Greece, Rhodes, 31/10-4/11, 1998
Co-ordinator: Dr. G. Giaccone
Lecture: Drug resistance and functional scintigraphy in NSCLC.

1. Photodynamic Therapy and apoptosis of tumour cells.

Italy, University of Padua, 22 July, 1997
Co-ordinator: Prof. Giulio Jori
Lecture: Bcl-2 and apoptosis.

B. National Congresses

1. Breast cancer radiotherapy planning according to stage and age
2. Hyperthermia and chemotherapy of soft tissue sarcomas
3. Radiotherapy for locally advanced inoperable rectal cancer
4. Preoperative radiotherapy for rectal cancer
5. Tumour Microenvironment and response to anti-cancer therapy
6. Radiotherapy for the treatment of malignant salivary gland tumors
7. Solar radiation and carcinogenesis
8. External beam radiotherapy for prostate cancer
9. Lactate dehydrogenase in lymphomas and other malignancies
10. Combination of chemotherapy and radiation in head neck cancer
11. Experience from the radioprotective action of amifostine
12. Hypoxia, Angiogenesis and resistance to radiotherapy and chemotherapy
13. The role of radiotherapy in the management of lymphomas
14. Novel radiotherapy approaches in breast cancer
15. Radiotherapy for breast cancer. The role of radiotherapy in the local control and survival of cancer patients
16. Interaction of radiation with drugs
17. Radiotherapy in the treatment of bone sarcomas
18. Radiotherapy for the tumours of the oral cavity
19. Therapeutic management of rectal adenocarcinoma
20. Combination of radiation with novel drugs
21. Combined therapy for head-neck cancer
22. Care of the cancer patient after the hospital
23. Radiotherapy and social issues
24. Applying clinical radiobiology
25. Molecular basis of hypoxia and radiotherapy
26. Radiotherapy for nasopharyngeal carcinomas
27. Radiotherapy and radio-chemotherapy for lung cancer

28. Treatment of cancer of the uterus and cervix
29. Adjuvant therapy for gastric cancer
30. Resistance to photodynamic therapy
31. Combined radio-chemotherapy
32. Postoperative radiotherapy for rectal cancer
33. Radiotherapy for operable lung cancer
34. Amifostine radioprotection
35. Radiotherapy and chemotherapy for gastric cancer
36. Angiogenesis and anti-angiogenic therapy in radiation oncology
37. VEGF/KDR angiogenic pathway as a target for cancer therapy
38. Radiation toxicity
39. Hypoxia and cancer therapy
40. Complications after radiotherapy for cancer of the oral cavity
41. Dealing with pain in oncology
42. Angiogenesis and resistance to cytotoxic therapy
43. Developments in radiation oncology
44. Radiotherapy in prostate cancer: presence and future

10. ORGANIZATION OF INTERNATIONAL CONGRESSES

Organizing Committee

1. 6th International Conference of Anticancer Research, Halkidiki, October 1998
2. 5th Biannual International Conference on Angiogenesis: From molecular to integrative pharmacology. Crete, July 1999
3. European School of Oncology ESO Advanced course on 'Tumour angiogenesis: implications in the prognosis and treatment of cancer'. Alexandroupolis, October 2000.
4. 6th Biannual International Meeting on Angiogenesis: Basic Science and Clinical Developments. Crete 26 June - 2 July 2001
5. Postgraduate course in Neuropathology and Urological Pathology. (In collaboration with the European Society of Pathology and the Royal London School of Medicine). Alexandroupolis, 11-13 October 2001
6. 3rd International Conference on new Laser technologies and applications. Patras 2002.
7. 7th Biennial International meeting. Angiogenesis: basic science and clinical applications, Crete 3-8 July 2003
8. 7th International Conference of Anticancer Research, 25-30 October 2004, Corfu, Greece
9. International Conference of Anticancer Research, October 17-22 October 2008, KOS, Greece

11. Editorial board of Journals

- *British Journal of Cancer* (<http://www.nature.com/bjc/about/editor.html>)
- *World Journal of Gastrointestinal Oncology* (<http://www.wjgnet.com/1948-5204/edboard.htm>)
- *Lasers in Health*

12. REVIEWER IN PEER REVIEW JOURNALS

127 papers

1. Science, 2. PLOS Medicine, 4. Gastroenterology, 5. American Journal of Pathology,
6. Journal of Clinical Oncology, 7. Cancer Research, 8. Oncogene, 28. JNCI
9. Clinical Cancer Research, 10. Journal of Pathology, 11. Neoplasia,
12. International Journal of Cancer, 13. British Journal of Cancer, 14. Cancer,
15. Int J Radiation Oncology Biology and Physics, 16. Int J Radiation Biology,
17. Cancer Letters, 18. Lung Cancer, 19. Journal of Photochemistry and Photobiology,
20. The Pharmacogenomics J, 21. Cancer Biology & Therapy, 22: Cancer Biomarkers
23. Nanomedicine, 24. Expert opinion of therapeutic targets, 25. Hippokratia 26.
- International Journal of Pharmaceutics 27. PLOS one, 28. Oncotarget, 29. Nature
- Communications, 30. Biomarkers

13. REVIEWER OF INTERNATIONAL RESEARCH PROPOSALS

- | | | | |
|----|--|----------|----------|
| 1. | Cancer Research UK | 3 | projects |
| 2. | Cancer Society of New Zeland | 1 | |
| | 3. The Eli and Edythe L. Broad Foundation | 3 | |
| | 4. Research Grants Council (RGC) of Hong Kong | 2 | |
| 5. | Health Research Board Ireland | 1 | |
| 6. | Fondation Contre le Cancer, Belgium | 1 | |
| 7. | Luxembourg National Research Fund (FNR) | 1 | |

Cancer Society of New Zeland

Wakefield House, 90 the Terrace, PO BOX 10847, Wellington

Tel: 6444947270 Fax: 6444947271

Application No 02-03/07

Applicant : Dr. Peter H Sykes

Project: Angiogenic factors in the endometrium: different regulation in tumor and normal tissues

Submitted : 26-11-2002

The Eli and Edythe L. Broad Foundation

Broad Medical Research Program

Inflammatory Bowel Disease Grants

10900 Wilshire Boulevard, 12th Floor, Los Angeles, California 90024-6532, U.S.A.

Telephone: 1-310-954-5093 Fax: 1-310-954-5092

E-mail: hkubinec@broadmedical.org

Applicant : Dr. Silvio Danese

Project: The contribution of platelet-endothelial interactions and implications for novel therapeutic approaches.

Submitted : July 2004

Continuation Application asked for review : November 2005

Review : grade 10/10.

Cancer Research UK

London WC2A 3PX, United Kingdom, Tel: 44-20-70616048 Fax: -44-20-70616004

Email: donia.sadik@cancer.org.uk

Applicant: Dr. Rupa Sarkar , Academic Surgical Unit, St James University Hospital, UK

Project: Regulation of lactate dehydrogenase (LDH) expression and its role in colorectal cancer invasion.

Submitted : 30-3-2005

The Eli and Edythe L. Broad Foundation

Broad Medical Research Program, Inflammatory Bowel Disease Grants

10900 Wilshire Boulevard, 12th Floor, Los Angeles, California 90024-6532, U.S.A.

Telephone: 1-310-954-5093 Fax: 1-310-954-5092

E-mail: hkubinec@broadmedical.org

Applicant : Professor Sean P. Colgan, PhD ; Cell and Molecular Pathology, Harvard Medical School, Brigham and Women's Hospital, USA

Project: Hypoxia inducible factors as therapeutic targets

Submitted : 15 -10- 2005

Research Grants Council (RGC) of Hong Kong

7F Shui On Centre, 6-8 Harbour Road, Wan Chai, Hong Kong, China

Telephone/Fax: -852-28451183, E-mail: RGC@ugc.edu.hk

Applicant : Professor Ann D King, Department of Diagnostic Radiology and Organ Imaging, CUHK

Project: CUHK4457/06M Detection of Nasopharyngeal carcinoma NPC using magnetic resonance imaging

Submitted : 15 -9-2005

Cancer Research UK

London WC2A 3PX, United Kingdom

Tel: 44-20-70616100, Fax: -44-20-70616005, Email: stuart.day@cancer.org.uk

Applicant: Dr. Rehman I , Academic Urology Unit, University of Sheffield, UK

Project: Lactate dehydrogenase and prostate cancer progression: is there a link ?.

Submitted : 3-5-2006

Health Research Board Ireland

Dublin , 73 Lower Baggot Street, Ireland

Tel: 353-1-6761176 Fax: -353-1-6130337, Email: www.hrb.ie

Applicant: Dr. Ann Hopkins , Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Ireland

Project: The contribution of senescence and hypoxia to a non-invasive phenotype in breast cancer.

Submitted : 17-1-2007

Cancer Research UK

London WC2A 3PX, United Kingdom, Tel: 44-20-70616048 Fax: -44-20-70616004

Email: Carolyn.Doughty@cancer.org.uk

Applicant: Dr. Roger Philips , University of Bradford, UK

Project: Manipulating the bioenergetic status of bladder cancer cell lines to potentiate the activity of EO9

Submitted : February 2008

The Eli and Edythe L. Broad Foundation

Broad Medical Research Program

Inflammatory Bowel Disease Grants

10900 Wilshire Boulevard, 12th Floor, Los Angeles, California 90024-6532, U.S.A.

Telephone: 1-310-954-5093 Fax: 1-310-954-5092

E-mail: hkubinec@broadmedical.org

Applicant : Professor P. Colgan, PhD (University of Colorado Health Sciences Center)

Project: Hypoxia Inducible Factors as Therapeutic Targets in IBD

Submitted : April 2008

Research Grants Council (RGC) of Hong KongUniversity Grants Committee Secretariat , 7/F Shui On Centre , 6 - 8 Harbour Road ,
Wanchai, Hong KongApplicant : Simon YK LAW, Professor in Gastrointestinal Surgery, Department of Surgery,
The University of Hong KongProject: Esophageal Squamous Cell Carcinoma Genomics: Insight into host genetics, tumor
development, and metastasis and translation into personalized medicine

Submitted : May 2013

Fondation Contre le Cancer, Belgium

Translational & Clinical Research Grants 2014

Applicant: Professor Vincent Bours, Medical Oncology, Universite de Liege

Project: Prediction of chemotherapy response by miRNA profiling in breast cancer.

Submitted: June 2014

Luxembourg National Research Fund (FNR)

Research programme CORE 2015


Applicant: Bassam Janji, LIH - Luxembourg Institute of Health

Project: Inhibition of tumor hypoxia using the non-psychoactive cannabinoid

Submitted: June 2015

14. BOOKS and Chapters

1. 'Angiogenesis. From the molecular to integrative Pharmacology'. Advances in Experimental Medicine and Biology, Volume 476
Chapter : **Microvessel density, thymidine phosphorylase expression and resistance of head and neck cancer to chemo-radiotherapy. M.I. Koukourakis**
Editor: ME Maragoudakis.
Kluwer Academic / Plenum Publishers, New York, 2000 (pp 285-290)
Κεφάλαιο: Thymidine phosphorylase and resistance of tumors to radiotherapy and chemotherapy
2. **Special issue on Tumor Angiogenesis,**
Edited by **M.I. Koukourakis**
Anticancer Research , Volume 21, Number 6b, November-December 2001, pp 4207-4383
International Institute of Anticancer Research Editions.
3. **Clinical Reviews: Amifostine**
Edited by **M.I. Koukourakis**
Medical Education Network, 2002, New York, NY, USA, pp 1-20

4. **'Methods Molecular Medicine: Lung Cancer'**, Volume 74, pp 357-373. 2003.
Editor: Barbara Driscoll. CRC PRESS / IEEE PRESS, UK
Chapter: Vascular endothelial growth factor expression in non-small cell lung cancer.
O'Byrne KJ, Goddard J, Giatromanolaki A, **Koukourakis MI.**
 7. **BOOK: Soft Tissue Tumors (in Greek)**
Chapter: Radiotherapy and Chemoterapy of Soft Tissue Tumors
 8. **BOOK: Radiosensitization and Radiochemotherapy of cancer: Biological basis and clinical practice. (in Greek)** (Book refernce fo Medical Students in the Democritu University of Thrace)
 9. **'Fifty years of Human Genetics'**
Editor: Oliver Mayo – Carolyn Leach, Wakefield Press 2007
Chapter: 'Anaximandros: bowing to the father of genetics'
 10. **'Methods of Cancer Diagnosis, Therapy and Prognosis'**
Editor: MA Hayat, Distinguished Professor of Biology, Kean University, NJ USA. ELSEVIER (2009).
Chapter: Colorectal cancer: lactate dehydrogenase (LDH) activity as a prognostic marker
- 


15. PUBLISHED STUDIES IN THE INTERNATIONAL LITERATURE

Total number	302	PUBMED
Citations (excluding self)	10380	SCOPUS
H-index	50	SCOPUS
Total Impact Factor	1103	
Mean Impact Factor	3.35	

PAPERS BY AREA OF RESEARCH

Clinical	96
Translational	168
Experimental	14
Reviews	24
TOTAL	301

Citations by year



Main co-authors

Co-author	Co-authored Documents
Giatromanolaki, Alexandra N.	196
Sivridis, Efthimios L.	141
Harris, Adrian L.	93
Gatter, Kevin C.	83

Table of Publications

JOURNAL	Impact Factor	No papers	Total IF
Journal of Clinical Oncology	18.42	<u>4</u>	73,68
Autophagy	11.75	<u>6</u>	70,50
American Journal of Gastroenterology	10.75	<u>2</u>	21,50
Blood	10.45	<u>1</u>	10,45
Cancer Research	9.32	<u>7</u>	65,24
Clinical Cancer Research	8.72	<u>16</u>	139,52
Cancer Treatment Reviews	7.58	<u>1</u>	7,58
Chest	7.48	<u>1</u>	7,48
Journal of Pathology	7.42	<u>8</u>	59,36
Modern Pathology	6.18	<u>3</u>	18,54
Cancer Letters	5.62	<u>2</u>	11,24
European Journal of Cancer	5.41	<u>2</u>	10,82
International Journal of Cancer	5.08	<u>3</u>	15,24
Cancer	4.88	<u>4</u>	19,52
Angiogenesis	4.86	<u>2</u>	9,72
Oncologist	4.86	<u>1</u>	4,86
British Journal of Cancer	4.83	<u>23</u>	111,09
American Journal of Pathology	4.59	<u>1</u>	4,59
Neoplasia	4.25	<u>1</u>	4,25
International Journal Radiation Oncology Biology Physics	4.17	<u>18</u>	75,06
Critical Reviews in Oncology Hematology	4.02	<u>1</u>	4,02
Journal of Immunotherapy	4.00	<u>1</u>	4,00
Lung Cancer	3.95	<u>4</u>	15,80
Cancer Immunology Immunotherapy	3.94	<u>1</u>	3,94
Clinical Nuclear Medicine	3.93	<u>1</u>	3,93
Seminars in Oncology	3.89	<u>3</u>	11,67
Gynecologic Oncology	3.77	<u>3</u>	11,31
Arthritis Research Therapy	3.75	<u>1</u>	3,75
Molecular Human Reproduction	3.74	<u>1</u>	3,74
Cancer Science	3.53	<u>2</u>	7,06
Clinical and Experimental Metastasis	3.49	<u>6</u>	20,94
Brain Topography	3.46	<u>1</u>	3,46
Clinical Oncology	3.39	<u>1</u>	3,39
Journal of Surgical Oncology	3.24	<u>1</u>	3,24
Plos One	3.23	<u>3</u>	9,69
Mediators Inflammation	3.22	<u>1</u>	3,22
Hematological Oncology	3.08	<u>1</u>	3,08
Cancer Biology and Therapy	3.07	<u>5</u>	15,35
American Journal of Clinical Oncology	3.06	<u>15</u>	45,90
European Journal of Surgical Oncology	3.00	<u>1</u>	3,00
Acta Oncologica	2.99	<u>2</u>	5,98
Digestive and Liver Disease	2.96	<u>1</u>	2,96
Journal of Clinical Pathology	2.91	<u>7</u>	20,37
Food and Chemical Toxicology	2.89	<u>1</u>	2,89
Leukemia and Lymphoma	2.89	<u>1</u>	2,89
Tumor Biology	2.84	<u>1</u>	2,84
Cancer Chemotherapy and Pharmacology	2.76	<u>1</u>	2,76
Urologic Oncology Seminars and Original Investigations	2.76	<u>3</u>	8,28
European Journal of Clinical Investigation	2.73	<u>1</u>	2,73
Cytokine	2.66	<u>2</u>	5,32
Virchows Archiv	2.65	<u>3</u>	7,95
Medical Oncology	2.63	<u>5</u>	13,15

Medical Physics	2.63	1	2,63
Lasers in Surgery and Medicine	2.61	1	2,61
Respiration	2.59	1	2,59
Colorectal Disease	2.44	1	2,44
International Journal of Colorectal Disease	2.44	2	4,88
Acta Obstetricia Et Gynecologica Scandinavica	2.42	1	2,42
Oncology	2.42	3	7,26
Breast Cancer	2.38	1	2,38
European Journal of Radiology	2.36	1	2,36
Integrative Cancer Therapies	2.36	1	2,36
Oncology Reports	2.30	1	2,30
Biochemical Biophysical Research Communications	2.29	3	6,87
Melanoma Research	2.28	2	4,56
Urology	2.28	1	2,28
Biomarkers	2.26	1	2,26
Inflammation	2.20	1	2,20
Journal of Spinal Disorders	2.20	1	2,20
Laryngoscope	2.14	1	2,14
Histopathology	2.09	3	6,27
Molecules	2.09	1	2,09
Clinical and Translational Oncology	2.07	1	2,07
APMIS	2.04	2	4,08
British Journal of Radiology	2.02	2	4,04
Applied Immunohistochemistry	2.01	1	2,01
Advances in Experimental Medicine and Biology	1.98	2	3,96
Anticancer Research	1.86	28	52,08
Anti Cancer Drugs	1.78	3	5,34
Gynecologic and Obstetric Investigation	1.69	1	1,69
International Journal of Radiation Biology	1.68	3	5,04
Nuclear Medicine Communications	1.67	2	3,34
European Journal of Cancer Care	1.56	1	1,56
Urologia Internationalis	1.42	1	1,42
Breast	1.41	1	1,41
American Journal of Dermatopathology	1.38	1	1,38
Tumori	1.27	2	2,54
Computerized Medical Imaging and Graphics	1.21	1	1,21
Dose Response	1.21	1	1,21
Journal of Applied Clinical Medical Physics	1.17	1	1,17
Oncology Research	1.05	3	3,15
In Vivo	0.97	3	2,91
International Journal of Surgical Pathology	0.95	3	2,85
Journal of Integrative Neuroscience	0.93	1	0,93
Medical Dosimetry	0.91	3	2,73
Radiation Protection Dosimetry	0.91	1	0,91
Acta Neurologica Belgica	0.59	1	0,59
Clinical Imaging	0.59	1	0,59
Acta Chirurgica Belgica	0.44	1	0,44
B Ent	0.43	1	0,43
Forum of Clinical Oncology		1	
Gazzetta Medica Italiana		1	
Hematology Oncology and Stem Cell Therapy		2	
Journal of Contemporary Brachytherapy		1	
Methods Mol Med		1	
Sarcoma		1	

PAPERS BY AREA OF RESEARCH

Clinical	96
Translational	168
Experimental	13
Reviews	23

CLINICAL TRIALS AND STUDIES (96 papers)

1: Pouliliou SE, Lialiaris TS, Dimitriou T, Giatromanolaki A, Papazoglou D, Pappa A, Pistevou K, Kalamida D, **KOUKOURAKIS MI**. Survival Fraction at 2 Gy and γ H2AX Expression Kinetics in Peripheral Blood Lymphocytes From Cancer Patients: Relationship With Acute Radiation-Induced Toxicities. *Int J Radiat Oncol Biol Phys*. 2015 Jul 1;92(3):667-74. doi: 10.1016/j.ijrobp.2015.02.023. Epub 2015 Apr 16. PubMed PMID: 25892583.

2: Karpathiou G, Giatromanolaki A, **KOUKOURAKIS MI**, Mihailidis V, Sivridis E, Bouros D, Froudarakis ME. Histological changes after radiation therapy in patients with lung cancer: a prospective study. *Anticancer Res*. 2014 Jun;34(6):3119-24. PubMed PMID: 24922681.

3: Kalaitzis C, **KOUKOURAKIS M**, Giannakopoulos S, Giatromanolaki A, Sivridis E, Bantis A, Touloupidis S. Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation. *Case Rep Urol*. 2014;2014:218628. doi: 10.1155/2014/218628. Epub 2014 Jan 29. PubMed PMID: 24600526; PubMed Central PMCID: PMC3926244.

4: Kyrgias G, Zygogianni A, Theodorou K, **KOUKOURAKIS M**, Oikonomou A, Kouvaris J, Kouloulis V. Accelerated Hypofractionated Whole-Breast Irradiation With Concomitant Daily Boost in Early Breast Cancer. *Am J Clin Oncol*. 2015 Aug;38(4):358-63. doi: 10.1097/COC.0b013e3182a46740. PubMed PMID: 23934132.

5: Gunn GB, **KOUKOURAKIS MI**, Mendoza TR, Cleeland CS, Rosenthal DI. Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. *Forum Clin Oncol*. 2012 Mar;3(1):29-31. PubMed PMID: 23439668; PubMed Central PMCID: PMC3576859.

6: Abatzoglou I, **KOUKOURAKIS M**, Konstantinides S. Reduction of the radiation dose received by interventional cardiologists following training in radiation protection. *Radiat Prot Dosimetry*. 2013 Jun;155(1):119-21. doi: 10.1093/rpd/ncs316. Epub 2012 Nov 25. PubMed PMID: 23185068.

7: **KOUKOURAKIS MI**, Papadopoulou A, Abatzoglou I, Panteliadou M, Sismanidou K, Touloupidis S. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. *Anticancer Res*. 2012 Oct;32(10):4561-8. PubMed PMID: 23060587.

8: **KOUKOURAKIS MI**, Panteliadou M, Abatzoglou IM, Sismanidou K, Sivridis E, Giatromanolaki A. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection. *Int J Radiat Oncol Biol Phys*. 2013 Jan 1;85(1):e7-13. doi: 10.1016/j.ijrobp.2012.08.017. Epub 2012 Oct 3. PubMed PMID: 23040218.

9: KOUKOURAKIS MI, Kyrgias G, Panteliadou M, Papadopoulou A, Tsiarkatsi M, Papachristou E, Bebeli M. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy. *Am J Clin Oncol*. 2013 Aug;36(4):338-43. doi: 10.1097/COC.0b013e318248d882. PubMed PMID: 22643562.

10: KOUKOURAKIS MI, Kyrgias G, Papadopoulou A, Panteliadou M, Giatromanolaki A, Sivridis E, Mavropoulou S, Kalogeris K, Nassos P, Milioudis N, Touloupidis S. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. *Anticancer Res*. 2011 May;31(5):1745-51. PubMed PMID: 21617234.

11: KOUKOURAKIS MI, Papadopoulou A, Kyrgias G. Long-term survival of a patient with multiple abdominal metastasis from endometrial carcinoma treated with multi-portal conformal re-irradiation and chemotherapy. *Hematol Oncol Stem Cell Ther*. 2011;4(1):45-7. PubMed PMID: 21460607.

12: Panteliadou M, Giatromanolaki A, Touloupidis S, Destouni E, Tsoutsou PG, Pantelis P, Abatzoglou I, Sismanidou K, KOUKOURAKIS MI. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC). *Urol Oncol*. 2012 Nov-Dec;30(6):813-20. doi: 10.1016/j.urolonc.2010.09.001. Epub 2010 Dec 16. PubMed PMID: 21163674.

13: KOUKOURAKIS MI, Pitsiava D, Giatromanolaki A, Kambouromiti G, Sivridis E, Kartalis G. Amifostine-related fever-rash during fractionated radiotherapy: diagnostic and predictive role of C-reactive protein. *Am J Clin Oncol*. 2011 Jun;34(3):281-5. doi: 10.1097/COC.0b013e3181dea7bd. PubMed PMID: 20838325.

14: KOUKOURAKIS MI, Giatromanolaki A, Tsoutsou P, Lyratzopoulos N, Pitiakoudis M, Kouklakis G, Chloropoulou PA, Manolas K, Sivridis E. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study. *Int J Radiat Oncol Biol Phys*. 2011 Jun 1;80(2):492-8. doi: 10.1016/j.ijrobp.2010.02.037. Epub 2010 Jun 30. PubMed PMID: 20584585.

15: Panteliadou M, Touloupidis S, Giatromanolaki A, Pistevou K, Kyrgias G, Tsoutsou P, Kalaitzis C, KOUKOURAKIS MI. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). *Med Oncol*. 2011 Dec;28(4):1356-62. doi: 10.1007/s12032-010-9544-x. Epub 2010 Apr 28. PubMed PMID: 20424934.

16: KOUKOURAKIS MI, Giatromanolaki A, Pitiakoudis M, Kouklakis G, Tsoutsou P, Abatzoglou I, Panteliadou M, Sismanidou K, Sivridis E, Boulikas T. Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. *Int J Radiat Oncol Biol Phys*. 2010 Sep 1;78(1):150-5. doi: 10.1016/j.ijrobp.2009.07.1733. PubMed PMID: 20138443.

17: KOUKOURAKIS MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, Sivridis E, Harris AL; Tumour and Angiogenesis Research Group. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. *Clin Cancer Res*. 2009 Nov 15;15(22):7069-76. doi: 10.1158/1078-0432.CCR-09-0688. Epub 2009 Nov 3. PubMed PMID: 19887481.

18: KOUKOURAKIS MI, Tsoutsou PG, Abatzoglou I, Soulimioti G, Sismanidou K, Liberis V, Giatromanolaki A, Sivridis E, Galazios G. Postoperative accelerated radiotherapy with

- cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer. *Tumori*. 2009 Jul-Aug;95(4):455-60. PubMed PMID: 19856656.
- 19: KOUKOURAKIS MI, Tsoutsou PG, Karpouzis A, Tsiarkatsi M, Karapantzos I, Daniilidis V, Kouskousis C. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. *Int J Radiat Oncol Biol Phys*. 2010 May 1;77(1):9-15. doi: 10.1016/j.ijrobp.2009.04.060. Epub 2009 Sep 8. PubMed PMID: 19744802.
- 20: Abatzoglou I, Anninos P, Tsalafoutas I, KOUKOURAKIS M. Multi-channel magnetoencephalogram on Alzheimer disease patients. *J Integr Neurosci*. 2009 Mar;8(1):13-22. PubMed PMID: 19412977.
- 21: KOUKOURAKIS G, Kouloulis V, KOUKOURAKIS M, Kouvaris J, Zacharias G, Gouliamos A. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer. *J BUON*. 2009 Jan-Mar;14(1):19-25. Review. PubMed PMID: 19373942.
- 22: KOUKOURAKIS MI, Tsoutsou PG, Abatzoglou I. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radiochemotherapy supported with amifostine. *Am J Clin Oncol*. 2009 Jun;32(3):258-61. doi: 10.1097/COC.0b013e3181845557. PubMed PMID: 19349852.
- 23: Polychronidis A, Tsaroucha AK, Perente S, Giatromanolaki A, KOUKOURAKIS M, Simopoulos C. Port-site metastasis of extrahepatic bile duct carcinoma after laparoscopic cholecystectomy without evidence of a primary tumour. *Acta Chir Belg*. 2008 Nov-Dec;108(6):768-70. PubMed PMID: 19241938.
- 24: KOUKOURAKIS GV, Baksevanis CN, Zambatis H, Gritzapis A, Maltezos E, Simopoulos C, KOUKOURAKIS MI. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer. *Int J Radiat Biol*. 2009 Jan;85(1):96-104. doi: 10.1080/09553000802635070. PubMed PMID: 19205988.
- 25: KOUKOURAKIS MI, Tsoutsou PG, Abatzoglou IM, Sismanidou K, Giatromanolaki A, Sivridis E. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report. *Int J Radiat Oncol Biol Phys*. 2009 Jul 15;74(4):1173-80. doi: 10.1016/j.ijrobp.2008.09.016. Epub 2008 Dec 6. PubMed PMID: 19058920.
- 26: KOUKOURAKIS MI, Simopoulos C, Pitiakoudis M, Lyratzopoulos N, Romanidis K, Giatromanolaki A, Polychronidis A, Kouklakis G, Sivridis E, Minopoulos G, Manolas K. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study. *Anticancer Res*. 2008 Sep-Oct;28(5B):3035-40. PubMed PMID: 19031952.
- 27: Abatzoglou I, Tsoutsou P, KOUKOURAKIS MI. A plesiotherapy technique for the post-operative treatment of skin cancer using Ir192 microSelectron. *J Appl Clin Med Phys*. 2008 Oct 29;9(4):2890. PubMed PMID: 19020493.
- 28: KOUKOURAKIS GV, Kouloulis VE, KOUKOURAKIS MJ, Zacharias GA, Papadimitriou C, Mystakidou K, Pistevou-Gompaki K, Kouvaris J, Gouliamos A. Granulosa cell tumor of the ovary: tumor review. *Integr Cancer Ther*. 2008 Sep;7(3):204-15. doi: 10.1177/1534735408322845. Review. PubMed PMID: 18815151.

- 29: KOUKOURAKIS GV, Kouloulis V, KOUKOURAKIS MJ, Zacharias GA, Zabatis H, Kouvaris J. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. *Molecules*. 2008 Aug 27;13(8):1897-922. Review. PubMed PMID: 18794792.
- 30: Zambatis C, Skarlatos J, KOUKOURAKIS M, Kosma L, Giatromanolaki A, Beroukas K, Yannakakis D. Concurrent hypofractionated radiotherapy and 5-Fluorouracil for advanced sarcomas of the bone. *Sarcoma*. 1998;2(1):25-8. doi: 10.1080/13577149878127. PubMed PMID: 18521229; PubMed Central PMCID: PMC2395373.
- 31: Tsoutsou PG, Froudarakis ME, Bouros D, KOUKOURAKIS MI. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). *Anticancer Res*. 2008 Mar-Apr;28(2B):1349-54. PubMed PMID:18505077.
- 32: KOUKOURAKIS MI, Patlakas G, Froudarakis ME, Kyrgias G, Skarlatos J, Abatzoglou I, Bougioukas G, Bouros D. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. *Anticancer Res*. 2007 Sep-Oct;27(5B):3625-31. PubMed PMID: 17972527.
- 33: Corti L, Toniolo L, Boso C, Colaut F, Fiore D, Muzzio PC, KOUKOURAKIS MI, Mazzarotto R, Pignataro M, Loreggian L, Sotti G. Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. *Lasers Surg Med*. 2007 Jun;39(5):394-402. PubMed PMID: 17565719.
- 34: KOUKOURAKIS MI, Mavanis I, Kouklakis G, Pitiakoudis M, Minopoulos G, Manolas C, Simopoulos C. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. *Am J Clin Oncol*. 2007 Jun;30(3):315-8. PubMed PMID: 17551312.
- 35: Danielides V, Katotomichelakis M, Homsoglou E, KOUKOURAKIS MI, Giatromanolaki A, Sivridis E. Squamous cell nose and a synchronous in-situ vocal cord carcinoma: a case report. *B-ENT*. 2007;3(1):45-8. PubMed PMID: 17451127.
- 36: KOUKOURAKIS MI, Tsolos C, Touloupidis S. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer. *Urology*. 2007 Feb;69(2):245-50. PubMed PMID: 17320657.
- 37: Mell LK, Malik R, Komaki R, Movsas B, Swann RS, Langer C, Antonadou D, KOUKOURAKIS M, Mundt AJ. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. *Int J Radiat Oncol Biol Phys*. 2007 May 1;68(1):111-8. Epub 2007 Feb 7. Review. PubMed PMID: 17289291.
- 38: KOUKOURAKIS MI, Abatzoglou I, Touloupidis S, Manavis I. Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer. *Med Phys*. 2007 Jan;34(1):76-80. PubMed PMID: 17278492.
- 39: Manavis J, Ambatzoglou J, Sismanidou K, KOUKOURAKIS MI. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery. *Am J Clin Oncol*. 2006 Oct;29(5):479-83. PubMed PMID: 17023783.
- 40: KOUKOURAKIS MI, Abatzoglou I, Sivridis L, Tsarkatsi M, Delidou H. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy. *Anticancer Res*. 2006 May-Jun;26(3B):2437-43. PubMed PMID: 16821629.

- 41: KOUKOURAKIS MI, Touloupidis S. External beam radiotherapy for prostate cancer: current position and trends. *Anticancer Res.* 2006 Jan-Feb;26(1B):485-94. Review. PubMed PMID: 16739309.
- 42: KOUKOURAKIS MI, Maltezos E. Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. *Anticancer Drugs.* 2006 Feb;17(2):133-8. Review. PubMed PMID: 16428930.
- 43: Patlakas G, Bouros D, Tsantekidou-Pozova S, KOUKOURAKIS MI. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. *Anticancer Res.* 2005 Mar-Apr;25(2B):1427-31. PubMed PMID: 15865101.
- 44: Antoniou PE, Anninos PA, Piperidou H, Adamopoulos A, Kotini A, KOUKOURAKIS MI, Sivridis E. Non linear analysis of magnetoencephalographic signals as a tool for assessing malignant lesions of the brain: first results. *Brain Topogr.* 2004 Winter;17(2):117-23. PubMed PMID: 15754877.
- 45: Manavis J, Sivridis L, KOUKOURAKIS MI. Nasopharyngeal carcinoma: the impact of CT-scan and of MRI on staging, radiotherapy treatment planning, and outcome of the disease. *Clin Imaging.* 2005 Mar-Apr;29(2):128-33. PubMed PMID: 15752969.
- 46: Pitiakoudis M, KOUKOURAKIS M, Tsaroucha A, Manavis J, Polychronidis A, Simopoulos C. Malignant retroperitoneal paraganglioma treated with concurrent radiotherapy and chemotherapy. *Clin Oncol (R Coll Radiol).* 2004 Dec;16(8):580-1. PubMed PMID: 15630855.
- 47: KOUKOURAKIS MI, Touloupidis S, Manavis J, Abatzoglou I, Sismanidou K, Sivridis L. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience. *Anticancer Res.* 2004 Sep-Oct;24(5B):3239-43. PubMed PMID: 15510617.
- 48: Boccia R, Anné PR, Bourhis J, Brizel D, Daly C, Holloway N 3rd, Hymes S, KOUKOURAKIS M, Kozloff M, Turner M, Wasserman T. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethylol (amifostine) cutaneous treatment advisory panel (ECTAP). *Int J Radiat Oncol Biol Phys.* 2004 Sep 1;60(1):302-9. Review. PubMed PMID: 15337569.
- 49: KOUKOURAKIS MI, Simopoulos C, Minopoulos G, Patlakas G, Polychronidis A, Limberis V, Romanides K, Pitiacoudis M, Manolas C. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. *Clin Cancer Res.* 2003 Aug 15;9(9):3288-93. PubMed PMID: 12960114.
- 50: KOUKOURAKIS MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S, Giatromanolaki A, Sivridis E. The effect of trastuzumab/docetaxel combination on breast cancer angiogenesis: dichotomous effect predictable by the HIFI alpha/VEGF pre-treatment status? *Anticancer Res.* 2003 Mar-Apr;23(2C):1673-80. PubMed PMID:12820439.
- 51: KOUKOURAKIS MI. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. *Semin Oncol.* 2002 Dec;29(6 Suppl 19):42-6. Review. PubMed PMID: 12577243.

- 52: Kakolyris S, Kouroussis C, KOUKOURAKIS M, Mavroudis D, Malas K, Vardakis N, Bozionelou V, Kalbakis K, Georgoulas V. A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. *Oncology*. 2002;63(3):213-8.
- 53: KOUKOURAKIS MI, Romanidis K, Froudarakis M, Kyrgias G, KOUKOURAKIS GV, Retalis G, Bahlitzanakis N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. *Br J Cancer*. 2002 Aug 12;87(4):385-92. Review. PubMed PMID: 12177774; PubMed Central PMCID: PMC2376133.
- 54: KOUKOURAKIS MI, Kapsoritakis A, Maltezos E, Potamiano S, Mouzas I, Kouroumalis H. Unexpected toxicity after low-dose docetaxel treatment of a cancer patient with clinically latent HCV-positive hepatic cirrhosis. *Anticancer Res*. 2002 Jul-Aug;22(4):2491-2. PubMed PMID: 12174950.
- 55: Kakolyris SS, Kouroussis C, KOUKOURAKIS M, Kalbakis K, Mavroudis D, Vardakis N, Georgoulas V. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. *Anticancer Res*. 2002 May-Jun;22(3):1891-6. PubMed PMID: 12168889.
- 56: KOUKOURAKIS MI, Giatromanolaki A, Kouroussis C, Kakolyris S, Sivridis E, Frangiadaki C, Retalis G, Georgoulas V; Tumor and Angiogenesis Research Group. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. *Int J Radiat Oncol Biol Phys*. 2002 Jan 1;52(1):144-55. PubMed PMID: 11777632.
- 57: KOUKOURAKIS MI, Yannakakis D. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae. *Anticancer Res*. 2001 Jul-Aug;21(4B):2973-8. PubMed PMID: 11712796.
- 58: Koukouraki S, KOUKOURAKIS MI, Vagios E, Velidaki A, Tsiftsis D, Karkavitsas N. The role of 99m Tc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. *Nucl Med Commun*. 2001 Nov;22(11):1243-8. PubMed PMID: 11606891.
- 59: Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Mavroudis D, Kalbakis K, Kotsakis A, Vardakis N, KOUKOURAKIS M, Romanos J, Georgoulas V. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. *Oncology*. 2001;60(3):207-13. PubMed PMID: 11340371.
- 60: KOUKOURAKIS MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. *Br J Cancer*. 2000 Nov;83(10):1281-6. PubMed PMID: 11044350; PubMed Central PMCID: PMC2408790.
- 61: Koukouraki S, Prassopoulos P, KOUKOURAKIS M, Velidaki A, Karkavitsas N. Tc-99m sestamibi scintigraphy: an effective method to predict the response of thymoma after radiotherapy. *Clin Nucl Med*. 2000 Sep;25(9):727-8. PubMed PMID: 10983766.
- 62: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy? *Int J Radiat Oncol Biol Phys*. 2000 Sep 1;48(2):545-53. PubMed PMID: 10974475.

- 63: Kotsakis A, Sarra E, Peraki M, KOUKOURAKIS M, Apostolaki S, Souglakos J, Mavromanomakis E, Vlachonikolis J, Georgoulis V. Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis. *Cancer*. 2000 Sep 15;89(6):1380-6. PubMed PMID: 11002234.
- 64: Braybrooke JP, Propper DJ, O'Byrne KJ, KOUKOURAKIS MI, Patterson AV, Houlbrook S, Love SD, Varcoe S, Taylor M, Ganesan TS, Talbot DC, Harris AL. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. *Br J Cancer*. 2000 Jul;83(2):219-24. PubMed PMID: 10901374; PubMed Central PMCID: PMC2363491.
- 65: KOUKOURAKIS MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulis V, Velidaki A, Archimandritis S, Karkavitsas NN. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy. *Acta Oncol*. 2000;39(2):207-11. PubMed PMID: 10859012.
- 66: Corti L, Skarlatos J, Boso C, Cardin F, Kosma L, KOUKOURAKIS MI, Giatromanolaki A, Norberto L, Shaffer M, Beroukas K. Outcome of patients receiving photodynamic therapy for early esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2000 May 1;47(2):419-24. PubMed PMID: 10802369.
- 67: KOUKOURAKIS MI, Flordellis CS, Giatromanolaki A, Koukouraki S, Kapsoritakis A, Potamianos S, Retalis G, Sivridis E, Salsaa B, Harris AL, Maragoudakis MI. Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis. *Clin Cancer Res*. 1999 Dec;5(12):3970-6. PubMed PMID: 10632327.
- 68: Kakolyris S, Kourousis C, KOUKOURAKIS M, Androulakis N, Vamvakas L, Agelaki S, Hatzidaki D, Samonis G, Tsiftsis D, Georgoulis V. First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. *Am J Clin Oncol*. 1999 Dec;22(6):568-72. PubMed PMID: 10597740.
- 69: KOUKOURAKIS MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulis V. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. *J Clin Oncol*. 2000 Jun;18(11):2226-33. PubMed PMID: 10829042.
- 70: KOUKOURAKIS MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N, Hellidonis ES. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. *J Clin Oncol*. 1999 Nov;17(11):3512-21. PubMed PMID: 10550149.
- 71: KOUKOURAKIS MI, Bizakis JG, Skoulakis CE, Kymizakis D, Giatromanolaki A, Papadakis CE, Prokopakis E, Amanakis Z, Hellidonis ES. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. *Anticancer Res*. 1999 May-Jun;19(3B):2305-9. PubMed PMID: 10472349.
- 72: KOUKOURAKIS MI, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulis V, Koumiotaki S, Christodoulou M, Kyrias G, Skarlatos J, Kostantelos J, Beroukas K. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. *Br J Cancer*. 1999 Aug;80(11):1792-6. PubMed PMID: 10468298; PubMed Central PMCID: PMC2363119.

- 73: O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, KOUKOURAKIS MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. *Br J Cancer*. 1999 Mar;79(9-10):1413-8. PubMed PMID: 10188884; PubMed Central PMCID: PMC2362707.
- 74: KOUKOURAKIS MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulas V. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. *Int J Radiat Oncol Biol Phys*. 1999 Jan 1;43(1):107-14. PubMed PMID: 9989521.
- 75: KOUKOURAKIS MI, Stefanaki I, Giatromanolaki A, Frangiadaki C, Armenaki A, Georgoulas V, Koumandakis E, Kranidis A, Helidonis E. Fractionated carboplatin radiosensitization: a phase I dose-escalation study. *Am J Clin Oncol*. 1998 Dec;21(6):595-601. PubMed PMID: 9856662.
- 76: KOUKOURAKIS MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulas V. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. *Eur J Cancer*. 1998 May;34(6):838-44. PubMed PMID: 9797695.
- 77: Kakolyris S, Samonis G, KOUKOURAKIS M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, Souglakos I, Agelaki S, Toloudis P, Georgoulas V. Treatment of non-small-cell lung cancer with prolonged oral etoposide. *Am J Clin Oncol*. 1998 Oct;21(5):505-8. PubMed PMID: 9781610.
- 78: Koumantakis E, Haralambakis Z, KOUKOURAKIS M, Mazonakis M, Haldeopoulos D, Papageorgiou N, Livas V, Froudarakis G, Varveris H. A pilot study on concurrent platinum chemotherapy and intracavitary brachytherapy for locally advanced cancer of the uterine cervix. *Br J Radiol*. 1998 May;71(845):552-7. PubMed PMID: 9691902.
- 79: O'Byrne KJ, KOUKOURAKIS MI, Saunders MP, Salisbury AJ, Isaacs R, Varcoe S, Taylor M, Ganesan TS, Harris AL, Talbot DC. Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. *Br J Cancer*. 1998 Jun;77(11):1950-6. PubMed PMID: 9667673; PubMed Central PMCID: PMC2150339.
- 80: Koukourakis I, Giaourakis G, Kouvidis G, Kivernitakis E, Blazos J, KOUKOURAKIS M. Screening school children for scoliosis on the island of Crete. *J Spinal Disord*. 1997 Dec;10(6):527-31. PubMed PMID: 9438820.
- 81: Kosma L, KOUKOURAKIS M, Skarlatos J, Zambatis C, Ardavanis A, Beroukas K, Yannakakis D. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer. *Am J Clin Oncol*. 1997 Dec;20(6):562-6. PubMed PMID: 9391540.
- 82: KOUKOURAKIS MI, Koukouraki S, Giatromanolaki A, Skarlatos J, Georgoulas V, Karkavitsas N. Non-small cell lung cancer functional imaging: increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment. *Clin Cancer Res*. 1997 May;3(5):749-54. PubMed PMID:9815745.
- 83: Koukouraki S, Damilakis J, Giatromanolaki A, Androulakis E, Karkavitsas N, KOUKOURAKIS M. Functional imaging of tumours with ⁹⁹Tcm-sestamibi pinhole scintigraphy. *Nucl Med Commun*. 1996 Nov;17(11):943-51. PubMed PMID: 8971865.

- 84: KOUKOURAKIS MI, Whitehouse RM, Giatromanolaki A, Saunders M, Kaklamanis L. Predicting distant failure in nasopharyngeal cancer. *Laryngoscope*. 1996 Jun;106(6):765-71. PubMed PMID: 8656965.
- 85: KOUKOURAKIS M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, Yannakakis D. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. *Int J Radiat Oncol Biol Phys*. 1996 Jan 15;34(2):315-22. PubMed PMID: 8567332.
- 86: Skarlatos J, Kosma L, KOUKOURAKIS M, Zambatis C, Kapsoritakis A, Moudier N, Yannakakis D. Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. *Int J Colorectal Dis*. 1996;11(5):206-10. PubMed PMID: 8951509.
- 87: Damilakis J, KOUKOURAKIS M, Hatjidakis A, Karabekios S, Gourtsoyiannis N. Radiation exposure to the hands of operators during angiographic procedures. *Eur J Radiol*. 1995 Nov;21(1):72-5. PubMed PMID: 8654464.
- 88: KOUKOURAKIS M, Skarlatos J, Kosma L, Giatromanolaki A, Yannakakis D. Radiotherapy alone for non-small cell lung carcinoma. Five-year disease-free survival and patterns of failure. *Acta Oncol*. 1995;34(4):525-30. PubMed PMID: 7605662.
- 89: Varveris C, KOUKOURAKIS M, Pissakas G, Maris T, Karpasitis N, Katsenis A, Kiparissiadis P, Gourtsoyiannis N. Unresectable colorectal-carcinoma - 10 years experience with patients treated with radical or palliative external-beam radiotherapy in Greece. *Oncol Rep*. 1994 Mar;1(2):445-51. PubMed PMID: 21607383.
- 90: KOUKOURAKIS MI, Damilakis J. LQ-based model for biological radiotherapy planning. *Med Dosim*. 1994 Winter;19(4):269-77. PubMed PMID: 7893363.
- 91: Skarlatos J, KOUKOURAKIS M, Zambatis H, Varveris C, Karvelas S, Tsopelas N, Yannakakis D. Transurethral ¹³⁷Cs medium dose rate radiotherapy as a boost for small-sized localized prostatic carcinomas. *Urol Int*. 1994;53(4):209-13. PubMed PMID: 7855938.
- 92: KOUKOURAKIS M, Zambatis H, Skarlatos J, Stamatelatos I, Georgolopoulou V, Rebelakos A, Yannakakis D. Transurethral radiotherapy for benign prostatic hypertrophy-related urethral obstruction. Dosimetry, ethics, and preliminary results. *Med Dosim*. 1994 Summer;19(2):67-72. PubMed PMID: 7522461.
- 93: KOUKOURAKIS MI, Varveris HA, Helidonis ES, Gourtsogiannis NH. CT-based radiotherapy treatment planning for cancer of the nasopharynx. *Comput Med Imaging Graph*. 1993 Mar-Apr;17(2):81-7. PubMed PMID: 8518997.
- 94: KOUKOURAKIS M, Scarlatos J, Yiannakakis D, Kordioliis N, Zambatis H, Sotiropoulou A. High dose hyperfractionated radiotherapy for adults with glioblastomas. *Med Dosim*. 1993 Fall;18(3):99-105. PubMed PMID: 8280367.
- 95: Giannakakis D, KOUKOURAKIS M, Sotiropoulou A, Zambatis H, Scarlatos J. Accelerated hyperfractionation of radiotherapy for rapidly growing inoperable breast cancer unresponsive to chemotherapy. *Tumori*. 1992 Oct 31;78(5):326-9. PubMed PMID: 1494805.

TRANSLATIONAL (168)

- 1: Giatromanolaki A, Kalamida D, Sivridis E, Karagounis IV, Gatter KC, Harris AL, KOUKOURAKIS MI. Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer. *Lung Cancer*. 2015 Oct;90(1):98-105. doi: 10.1016/j.lungcan.2015.07.008. Epub 2015 Jul 26. PubMed PMID: 26264650.
- 2: KOUKOURAKIS MI, Kalamida D, Mitrakas A, Pouliliou S, Kalamida S, Sivridis E, Giatromanolaki A. Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer. *Biochem Biophys Res Commun*. 2015 May 29;461(2):268-74. doi: 10.1016/j.bbrc.2015.04.014. Epub 2015 Apr 15. PubMed PMID: 25887800.
- 3: Giatromanolaki A, Sivridis E, Mitrakas A, Kalamida D, Zois CE, Haider S, Piperidou C, Pappa A, Gatter KC, Harris AL, KOUKOURAKIS MI. Autophagy and lysosomal related protein expression patterns in human glioblastoma. *Cancer Biol Ther*. 2014;15(11):1468-78. doi: 10.4161/15384047.2014.955719. PubMed PMID: 25482944.
- 4: KOUKOURAKIS MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, Ferrozzi F, Harris AL, Generali D. Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. *Br J Cancer*. 2014 Apr 29;110(9):2209-16. doi: 10.1038/bjc.2014.196. Epub 2014 Apr 10. PubMed PMID: 24722179; PubMed Central PMCID: PMC4007245.
- 5: KOUKOURAKIS MI, Giatromanolaki A, Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S, Sivridis E. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. *Br J Cancer*. 2014 Apr 29;110(9):2217-23. doi: 10.1038/bjc.2014.158. Epub 2014 Apr 8. PubMed PMID: 24714743; PubMed Central PMCID: PMC4007238.
- 6: Kontomanolis E, Panteliadou M, Giatromanolaki A, Pouliliou S, Efremidou E, Limberis V, Galazios G, Sivridis E, KOUKOURAKIS MI. Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis. *Med Oncol*. 2014 May;31(5):945. doi: 10.1007/s12032-014-0945-0. Epub 2014 Apr 3. PubMed PMID: 24696220.
- 7: Anevlavis S, Kouliatsis G, Sotiriou I, KOUKOURAKIS MI, Archontogeorgis K, Karpathiou G, Giatromanolaki A, Froudarakis ME. Prognostic factors in patients presenting with pleural effusion revealing malignancy. *Respiration*. 2014;87(4):311-6. doi: 10.1159/000356764. Epub 2014 Jan 22. PubMed PMID:
- 8: Giatromanolaki A, Sivridis E, Mendrinou S, Koutsopoulos AV, KOUKOURAKIS MI. Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. *Urol Oncol*. 2014 Jan;32(1):39.e11-8. doi: 10.1016/j.urolonc.2013.04.003. Epub 2013 Jun 17. PubMed PMID: 23787295.
- 9: Giatromanolaki A, KOUKOURAKIS MI, Pouliliou S, Gatter KC, Pezzella F, Harris AL, Sivridis E. Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. *Hematol Oncol Stem Cell Ther*. 2013 Mar;6(1):20-5. doi: 10.1016/j.hemonc.2013.02.001. Epub 2013 Feb 28. PubMed PMID: 23664601.

- 10: KOUKOURAKIS MI, Giatromanolaki A, Zois CE, Sivridis E. LC3 immunostaining pitfalls. *Histopathology*. 2013 May;62(6):962-3. doi: 10.1111/his.12080. Epub 2013 Mar 26. PubMed PMID: 23530618.
- 11: Giatromanolaki A, KOUKOURAKIS MI, Koutsopoulos AV, Harris AL, Gatter KC, Sivridis E. Autophagy and hypoxia in colonic adenomas related to aggressive features. *Colorectal Dis*. 2013 May;15(5):e223-30. doi: 10.1111/codi.12147. PubMed PMID: 23351172.
- 12: Karpathiou G, Sivridis E, KOUKOURAKIS M, Mikroulis D, Bouros D, Froudarakis M, Bougioukas G, Maltezos E, Giatromanolaki A. Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. *APMIS*. 2013 Jul;121(7):592-604. doi: 10.1111/apm.12026. Epub 2012 Dec 8. PubMed PMID: 23216071.
- 13: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC). *Angiogenesis*. 2013 Apr;16(2):343-51. doi: 10.1007/s10456-012-9318-5. Epub 2012 Oct 30. PubMed PMID: 23108591.
- 14: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. *Br J Cancer*. 2012 Sep 25;107(7):1044-50. doi: 10.1038/bjc.2012.369. Epub 2012 Aug 21. PubMed PMID: 22910317; PubMed Central PMCID: PMC3461163.
- 15: Giatromanolaki A, KOUKOURAKIS MI, Koutsopoulos A, Mendrinou S, Sivridis E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. *Cancer Biol Ther*. 2012 Nov;13(13):1284-9. doi: 10.4161/cbt.21785. Epub 2012 Aug 16. PubMed PMID: 22895074; PubMed Central PMCID: PMC3493436.
- 16: KOUKOURAKIS MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. *Br J Cancer*. 2012 Feb 28;106(5):846-53. doi: 10.1038/bjc.2012.33. Epub 2012 Feb 14. PubMed PMID: 22333601; PubMed Central PMCID: PMC3305970.
- 17: Sivridis E, KOUKOURAKIS MI, Mendrinou SE, Touloupidis S, Giatromanolaki A. Patterns of autophagy in urothelial cell carcinomas--the significance of "stone-like" structures (SLS) in transurethral resection biopsies. *Urol Oncol*. 2013 Oct;31(7):1254-60. doi: 10.1016/j.urolonc.2011.12.016. Epub 2012 Jan 24. PubMed PMID: 22281431.
- 18: Giatromanolaki A, Sivridis E, Bechrakis NE, Willerding G, St Charitoudis G, Foerster MH, Gatter KC, Harris AL, KOUKOURAKIS MI. Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2 α and survival. *Clin Exp Metastasis*. 2012 Jan;29(1):11-7. doi: 10.1007/s10585-011-9424-6. Epub 2011 Oct 9. PubMed PMID: 21984395.
- 19: Giatromanolaki A, KOUKOURAKIS MI, Koutsopoulos A, Chloropoulou P, Liberis V, Sivridis E. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. *Gynecol Oncol*. 2011 Oct;123(1):147-51. doi: 10.1016/j.ygyno.2011.06.023. Epub 2011 Jul 8. PubMed PMID: 21741077.
- 20: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. *Clin Cancer Res*. 2011 Jul

- 15;17(14):4892-900. doi: 10.1158/1078-0432.CCR-10-2918. Epub 2011 Jun 1. PubMed PMID: 21632858; PubMed Central PMCID: PMC3145151.
- 21: Sivridis E, KOUKOURAKIS MI, Mendrinou SE, Karpouzis A, Fiska A, Kouskoukis C, Giatromanolaki A. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. *Melanoma Res.* 2011 Jun;21(3):188-95. doi: 10.1097/CMR.0b013e328346612c. PubMed PMID: 21537144.
- 22: Giatromanolaki AN, Charitoudis GS, Bechrakis NE, Kozobolis VP, KOUKOURAKIS MI, Foerster MH, Sivridis EL. Autophagy patterns and prognosis in uveal melanomas. *Mod Pathol.* 2011 Aug;24(8):1036-45. doi: 10.1038/modpathol.2011.63. Epub 2011 Apr 15. PubMed PMID: 21499230.
- 23: Sivridis E, Giatromanolaki A, Karpathiou G, Karpouzis A, Kouskoukis C, KOUKOURAKIS MI. LC3A-positive "stone-like" structures in cutaneous squamous cell carcinomas. *Am J Dermatopathol.* 2011 May;33(3):285-90. doi: 10.1097/DAD.0b013e3181f10de0. PubMed PMID: 21430508.
- 24: KOUKOURAKIS MI, Limberis V, Tentis I, Kontomanolis E, Kortsaris A, Sivridis E, Giatromanolaki A. Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. *Cytokine.* 2011 Mar;53(3):370-5. doi: 10.1016/j.cyto.2010.12.007. Epub 2011 Jan 3. PubMed PMID: 21208810.
- 25: Karpathiou G, Sivridis E, KOUKOURAKIS MI, Mikroulis D, Bouros D, Froudarakis ME, Giatromanolaki A. Light-chain 3A autophagic activity and prognostic significance in non-small cell lung carcinomas. *Chest.* 2011 Jul;140(1):127-34. doi: 10.1378/chest.10-1831. Epub 2010 Dec 9. PubMed PMID: 21148243.
- 26: Sivridis E, Giatromanolaki A, Liberis V, KOUKOURAKIS MI. Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS): what is destined for the atypical endometrial hyperplasia? *Autophagy.* 2011 Jan;7(1):74-82. Epub 2011 Jan 1. PubMed PMID: 21099253.
- 27: Giatromanolaki A, KOUKOURAKIS MI, Harris AL, Polychronidis A, Gatter KC, Sivridis E. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. *J Clin Pathol.* 2010 Oct;63(10):867-72. doi: 10.1136/jcp.2010.079525. PubMed PMID: 20876316.
- 28: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Pitiakoudis M, Gatter KC, Harris AL. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. *Br J Cancer.* 2010 Oct 12;103(8):1209-14. doi: 10.1038/sj.bjc.6605904. Epub 2010 Sep 14. PubMed PMID: 20842118; PubMed Central PMCID: PMC2967071.
- 29: Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, KOUKOURAKIS MI, Sivridis E, Gatter KC. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. *Anticancer Res.* 2010 Jul;30(7):2831-6. PubMed PMID: 20683019.
- 30: Giatromanolaki A, Lyberakidis G, Lyratzopoulos N, KOUKOURAKIS MI, Sivridis E, Manolas C. Angiogenesis and angiogenic factor expression in thyroid cancer. *J BUON.* 2010 Apr-Jun;15(2):357-61. PubMed PMID: 20658735.
- 31: Sivridis E, Giatromanolaki A, Zois C, KOUKOURAKIS MI. The "stone-like" pattern of autophagy in human epithelial tumors and tumor-like lesions: an approach to the clinical outcome. *Autophagy.* 2010 Aug;6(6):830-3. Epub 2010 Aug 4. PubMed PMID: 20622525.

- 32: Eleftheriadis SG, Sivridis E, Koutsopoulos A, Galatoudis ZG, Chloropoulou PA, KOUKOURAKIS MI, Didilis VN, Bougioukas GI, Giatromanolaki A. One-lung ventilation and HIF1 α expression in lung cancer and pneumothorax. *Anticancer Res.* 2010 Apr;30(4):1143-8. PubMed PMID: 20530420.
- 33: Giatromanolaki A, Sivridis E, Fiska A, KOUKOURAKIS MI. The CD44+/CD24-phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. *Med Oncol.* 2011 Sep;28(3):745-52. doi: 10.1007/s12032-010-9530-3. Epub 2010 Apr 20. PubMed PMID: 20405247.
- 34: Sivridis E, KOUKOURAKIS MI, Zois CE, Ledaki I, Ferguson DJ, Harris AL, Gatter KC, Giatromanolaki A. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. *Am J Pathol.* 2010 May;176(5):2477-89. doi: 10.2353/ajpath.2010.090049. Epub 2010 Apr 9. PubMed PMID: 20382705; PubMed Central PMCID: PMC2861112.
- 35: KOUKOURAKIS MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris AL. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. *Oncology.* 2009;77(5):285-92. doi: 10.1159/000259260. Epub 2009 Nov 16. PubMed PMID: 19923867.
- 36: Giatromanolaki A, Fiska A, Pitsiava D, Kartalis G, KOUKOURAKIS MI, Sivridis E. Erythropoietin receptors in endometrial carcinoma as related to HIF1 α and VEGF expression. *In Vivo.* 2009 Sep-Oct;23(5):699-703. PubMed PMID: 19779103.
- 37: Sivridis E, Stamos C, Fiska A, Nikolettos N, KOUKOURAKIS MI, Giatromanolaki A. c-erbB-2 and the "triple-state" in early breast carcinomas. *Med Oncol.* 2010 Sep;27(3):578-84. doi: 10.1007/s12032-009-9252-6. Epub 2009 Jun 23. PubMed PMID: 19548127.
- 38: KOUKOURAKIS MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. *Inflammation.* 2009 Jun;32(3):169-75. doi: 10.1007/s10753-009-9116-4. PubMed PMID: 19373547.
- 39: KOUKOURAKIS MI, Kontomanolis E, Giatromanolaki A, Sivridis E, Liberis V. Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. *Gynecol Obstet Invest.* 2009;67(3):162-8. doi: 10.1159/000183250. Epub 2008 Dec 16. PubMed PMID: 19088479.
- 40: Giatromanolaki A, KOUKOURAKIS MI, Pezzella F, Sivridis E, Turley H, Harris AL, Gatter KC. Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. *Leuk Lymphoma.* 2008 Nov;49(11):2181-6. doi: 10.1080/10428190802450629. PubMed PMID: 19021062.
- 41: Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, KOUKOURAKIS ML, Harris AL. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. *Br J Cancer.* 2008 Jun 17;98(12):1975-84. doi: 10.1038/sj.bjc.6604356. Epub 2008 Jun 10. PubMed PMID: 18542064; PubMed Central PMCID: PMC2441961.
- 42: Giatromanolaki A, Bates GJ, KOUKOURAKIS MI, Sivridis E, Gatter KC, Harris AL, Banham AH. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. *Gynecol Oncol.* 2008 Aug;110(2):216-21. doi: 10.1016/j.ygyno.2008.04.021. Epub 2008 Jun 3. PubMed PMID: 18533240.

- 43: Giatromanolaki A, KOUKOURAKIS MI, Pezzella F, Sivridis E, Turley H, Harris AL, Gatter KC. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. *Hematol Oncol*. 2008 Dec;26(4):219-24. doi: 10.1002/hon.861. PubMed PMID: 18461646.
- 44: Giatromanolaki A, Sivridis E, Papazoglou D, KOUKOURAKIS MI, Maltezos E. Human papillomavirus in endometrial adenocarcinomas: infectious agent or a mere "passenger"? *Infect Dis Obstet Gynecol*. 2007;2007:60549. doi: 10.1155/2007/60549. PubMed PMID: 18274613; PubMed Central PMCID: PMC2233766.
- 45: Giatromanolaki A, KOUKOURAKIS MI, Pezzella F, Turley H, Sivridis E, Bouros D, Bougioukas G, Harris AL, Gatter KC. Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. *Cancer Lett*. 2008 Apr 8;262(1):87-93. doi: 10.1016/j.canlet.2007.11.041. Epub 2008 Jan 9. PubMed PMID: 18187257.
- 46: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Chlouverakis G, Vourvouhaki E, Turley H, Harris AL, Gatter KC. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. *Eur J Clin Invest*. 2007 Nov;37(11):878-86. Epub 2007 Sep 20. PubMed PMID: 17883421.
- 47: KOUKOURAKIS MI, Giatromanolaki A, Bougioukas G, Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. *Cancer Biol Ther*. 2007 Sep;6(9):1476-9. Epub 2007 Jun 27. PubMed PMID: 17881895.
- 48: KOUKOURAKIS MI, Giatromanolaki A, Danielidis V, Sivridis E. Hypoxia inducible factor (HIF1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. *Int J Radiat Biol*. 2008 Jan;84(1):47-52. PubMed PMID: 17852557.
- 49: Abatzoglou I, Anninos P, Adamopoulos A, KOUKOURAKIS M. Nonlinear analysis of brain magnetoencephalographic activity in Alzheimer disease patients. *Acta Neurol Belg*. 2007 Jun;107(2):34-9. PubMed PMID: 17710838.
- 50: Giatromanolaki A, KOUKOURAKIS MI, Gatter KC, Harris AL, Sivridis E. BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1alpha pathway and prognosis. *J Clin Pathol*. 2008 Feb;61(2):217-20. Epub 2007 May 18. PubMed PMID: 17513511.
- 51: Giatromanolaki A, Kotsiou S, KOUKOURAKIS MI, Sivridis E. Angiogenic factor expression in hepatic cirrhosis. *Mediators Inflamm*. 2007;2007:67187. Epub 2007 Feb 28. PubMed PMID: 17497037; PubMed Central PMCID: PMC1847476.
- 52: Giatromanolaki A, KOUKOURAKIS MI, Simopoulos C, Sivridis E. Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1alpha phenotype. *Cancer Biol Ther*. 2007 Feb;6(2):153-5. Epub 2007 Feb 26. PubMed PMID: 17224643.
- 53: KOUKOURAKIS MI, Pitiakoudis M, Giatromanolaki A, Tsarouha A, Polychronidis A, Sivridis E, Simopoulos C. Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. *Cancer Sci*. 2006 Oct;97(10):1056-60. PubMed PMID: 16984378.

- 54: Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, KOUKOURAKIS MI. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. *J Surg Oncol*. 2006 Sep 1;94(3):242-7. PubMed PMID: 16900513.
- 55: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. *J Clin Oncol*. 2006 Sep 10;24(26):4301-8. Epub 2006 Aug 8. PubMed PMID: 16896001.
- 56: KOUKOURAKIS MI, Papazoglou D, Giatromanolaki A, Panagopoulos I, Maltezos E, Harris AL, Gatter KC, Sivridis E. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. *Lung Cancer*. 2006 Sep;53(3):257-62. Epub 2006 Jul 11. PubMed PMID: 16837101.
- 57: Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, KOUKOURAKIS MI; Tumour and Angiogenesis Research Group. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. *Gynecol Oncol*. 2006 Dec;103(3):912-8. Epub 2006 Jul 11. PubMed PMID: 16837029.
- 58: KOUKOURAKIS MI, Giatromanolaki A, Polychronidis A, Simopoulos C, Gatter KC, Harris AL, Sivridis E. Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. *Cancer Sci*. 2006 Jul;97(7):582-8. PubMed PMID: 16827797.
- 59: Giatromanolaki A, KOUKOURAKIS MI, Turley H, Sivridis E, Harris AL, Gatter KC; Tumour and Angiogenesis Research Group. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. *Mod Pathol*. 2006 May;19(5):701-7. PubMed PMID: 16557278.
- 60: Giatromanolaki A, Sivridis E, Fiska A, KOUKOURAKIS MI. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. *Appl Immunohistochem Mol Morphol*. 2006 Mar;14(1):78-82. PubMed PMID: 16540735.
- 61: KOUKOURAKIS MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. *Cancer Res*. 2006 Jan 15;66(2):632-7. PubMed PMID: 16423989.
- 62: KOUKOURAKIS MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. *J Clin Oncol*. 2006 Feb 10;24(5):727-35. Epub 2006 Jan 17. PubMed PMID: 16418497.
- 63: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumour and Angiogenesis Research Group. Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. *Clin Cancer Res*. 2005 Dec 15;11(24 Pt 1):8653-60. PubMed PMID: 16361550.
- 64: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Gatter KC, Harris AL, Banham AH. Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. *Mod Pathol*. 2006 Jan;19(1):9-16. PubMed PMID: 16258506.

65: KOUKOURAKIS MI, Manavis J, Simopoulos C, Liberis V, Giatromanolaki A, Sivridis E. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. *Am J Clin Oncol*. 2005 Oct;28(5):495-500. PubMed PMID: 16199990.

66: Sivridis E, Giatromanolaki A, KOUKOURAKIS MI. Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. *J Clin Pathol*. 2005 Oct;58(10):1033-8. PubMed PMID: 16189147; PubMed Central PMCID: PMC1770734.

67: Sivridis E, Giatromanolaki A, Galazios G, KOUKOURAKIS MI. Node-related factors and survival in node-positive breast carcinomas. *Breast*. 2006 Jun;15(3):382-9. Epub 2005 Aug 30. PubMed PMID: 16135406.

68: KOUKOURAKIS MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. *Clin Exp Metastasis*. 2005;22(1):25-30. PubMed PMID: 16132575.

69: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumor and Angiogenesis Research Group. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. *Neoplasia*. 2005 Jan;7(1):1-6. PubMed PMID: 15736311; PubMed Central PMCID: PMC1490315.

70: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Simopoulos C, Gatter KC, Harris AL, Jackson DG. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. *J Clin Pathol*. 2005 Feb;58(2):202-6. PubMed PMID: 15677543; PubMed Central PMCID: PMC1770560.

71: Giatromanolaki A, KOUKOURAKIS MI, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, Sivridis E. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. *Clin Cancer Res*. 2004 Dec 1;10(23):7972-7. PubMed PMID: 15585632.

72: KOUKOURAKIS MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. *Lung Cancer*. 2004 Dec;46(3):293-8.

73: Giatromanolaki A, Sivridis E, Tsikouras P, Manavis I, Maroulis G, KOUKOURAKIS MI. Angiogenesis and vascular survival ability in ovarian adenocarcinomas. *Virchows Arch*. 2004 Nov;445(5):521-6. Epub 2004 Sep 9. PubMed PMID: 15365829.

74: Giatromanolaki A, KOUKOURAKIS MI, Sowter HM, Sivridis E, Gibson S, Gatter KC, Harris AL. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. *Clin Cancer Res*. 2004 Aug 15;10(16):5566-71. PubMed PMID: 15328198.

75: Giatromanolaki A, KOUKOURAKIS MI, Ritis K, Mimidis K, Sivridis E. Interferon regulatory factor-1 (IRF-1) suppression and derepression during endometrial tumorigenesis and cancer progression. *Cytokine*. 2004 May 21;26(4):164-8. PubMed PMID: 15149633.

76: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Pastorek J, Karapantzos I, Gatter KC, Harris AL; Tumor and Angiogenesis Research Group. Hypoxia-activated tumor pathways of

angiogenesis and pH regulation independent of anemia in head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* 2004 May 1;59(1):67-71. PubMed PMID: 15093900.

77: Papazoglou D, Galazios G, KOUKOURAKIS MI, Kontomanolis EN, Maltezos E. Association of -634G/C and 936C/T polymorphisms of the vascular endothelial growth factor with spontaneous preterm delivery. *Acta Obstet Gynecol Scand.* 2004 May;83(5):461-5. PubMed PMID: 15059159.

78: Papazoglou D, Galazios G, KOUKOURAKIS MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, Maltezos E. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. *Mol Hum Reprod.* 2004 May;10(5):321-4. Epub 2004 Mar 2. PubMed PMID: 14997002.

79: Papadopoulos I, Giatromanolaki A, KOUKOURAKIS MI, Sivridis E. Tumour angiogenic activity and vascular survival ability in bladder carcinoma. *J Clin Pathol.* 2004 Mar;57(3):250-5. PubMed PMID: 14990594; PubMed Central PMCID: PMC1770238.

80: Giatromanolaki A, KOUKOURAKIS MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulis V. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. *Int J Cancer.* 2004 Feb 10;108(4):620-7. PubMed PMID: 14696130.

81: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E; Tumour and Angiogenesis Research Group. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. *Tumour Biol.* 2003 Aug-Sep;24(4):199-202. PubMed PMID: 14654714.

82: Giatromanolaki A, KOUKOURAKIS MI, Simopoulos C, Polychronidis A, Sivridis E. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. *Eur J Surg Oncol.* 2003 Dec;29(10):879-83. PubMed PMID: 14624781.

83: KOUKOURAKIS MI, Giatromanolaki A, Chong W, Simopoulos C, Polychronidis A, Sivridis E, Harris AL. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. *Cancer Chemother Pharmacol.* 2004 Jan;53(1):8-14. Epub 2003 Oct 22. PubMed PMID: 14574457.

84: Kaklamanis L, Kakolyris S, Turley H, KOUKOURAKIS M, Biddolph S, Gatter KC, Harris AL. Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas. *Angiogenesis.* 1998;2(1):49-55. PubMed PMID: 14517375.

85: Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, KOUKOURAKIS MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. *Melanoma Res.* 2003 Oct;13(5):493-501. PubMed PMID: 14512791.

86: KOUKOURAKIS MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. *Cancer Res.* 2003 Sep 1;63(17):5376-80. PubMed PMID: 14500371.

87: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL; Tumour and Angiogenesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic

- factor production and poor prognosis. *Br J Cancer*. 2003 Sep 1;89(5):877-85. PubMed PMID: 12942121; PubMed Central PMCID: PMC2394471.
- 88: Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, KOUKOURAKIS MI. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther*. 2003;5(4):R193-201. Epub 2003 Apr 29. PubMed PMID: 12823854; PubMed Central PMCID: PMC165055.
- 89: Kapsoritakis A, Sfridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, Sivridis E, KOUKOURAKIS MI. Vascular endothelial growth factor in inflammatory bowel disease. *Int J Colorectal Dis*. 2003 Sep;18(5):418-22. Epub 2003 May 22. PubMed PMID: 12761641.
- 90: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Turley H, Wykoff CC, Gatter KC, Harris AL. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. *J Pathol*. 2003 Jun;200(2):222-8. PubMed PMID: 12754744.
- 91: KOUKOURAKIS MI, Giatromanolaki A, Galazios G, Sivridis E. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference? *Br J Cancer*. 2003 Mar 10;88(5):711-7. PubMed PMID: 12618880; PubMed Central PMCID: PMC2376345.
- 92: Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL, KOUKOURAKIS MI. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. *J Clin Pathol*. 2003 Mar;56(3):209-13. PubMed PMID: 12610101; PubMed Central PMCID: PMC1769899.
- 93: KOUKOURAKIS MI, Manolas C, Minopoulos G, Giatromanolaki A, Sivridis E. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast. *Int J Surg Pathol*. 2003 Jan;11(1):29-34. PubMed PMID: 12598915.
- 94: KOUKOURAKIS MI, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. *Cancer Immunol Immunother*. 2003 Feb;52(2):127-31. Epub 2003 Feb 4. PubMed PMID: 12594577.
- 95: Giatromanolaki A, Sivridis E, Maltezos E, KOUKOURAKIS MI. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. *Semin Oncol*. 2002 Dec;29(6 Suppl 19):14-21. PubMed PMID: 12577238.
- 96: Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, KOUKOURAKIS MI. Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. *Clin Exp Metastasis*. 2002;19(8):673-9. PubMed PMID: 12553372.
- 97: KOUKOURAKIS MI, Giatromanolaki A, Liberis V, Sivridis E. Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer. *Anticancer Res*. 2002 Nov-Dec;22(6C):4137-40. PubMed PMID: 12553044.
- 98: O'Byrne KJ, Goddard J, Giatromanolaki A, KOUKOURAKIS MI. Vascular endothelial growth factor expression in non-small cell lung cancer. *Methods Mol Med*. 2003;74:357-73. PubMed PMID: 12415708.

99: Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, KOUKOURAKIS MI. Thymidine phosphorylase expression in gallbladder adenocarcinomas. *Int J Surg Pathol*. 2002 Jul;10(3):181-8. PubMed PMID: 12232571.

100: Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, KOUKOURAKIS MI; Tumor and Angiogenesis Research Group. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. *Cancer*. 2002 Sep 1;95(5):1055-63. PubMed PMID: 12209691.

101: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2002 Aug 1;53(5):1192-202. PubMed PMID: 12128120.

102: Giatromanolaki A, Sivridis E, Minopoulos G, Polychronidis A, Manolas C, Simopoulos C, KOUKOURAKIS MI. Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. *Clin Cancer Res*. 2002 May;8(5):1185-91. PubMed PMID: 12006536.

103: Sivridis E, Giatromanolaki A, Papadopoulos I, Gatter KC, Harris AL, KOUKOURAKIS MI. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. *Br J Cancer*. 2002 May 6;86(9):1465-71. PubMed PMID: 11986782; PubMed Central PMCID: PMC2375369.

104: Kapsoritakis AN, Potamianos SP, KOUKOURAKIS MI, Tzardi M, Mouzas IA, Roussomoustakaki M, Alexandrakis G, Kouroumalis EA. Diminutive polyps of large bowel should be an early target for endoscopic treatment. *Dig Liver Dis*. 2002 Feb;34(2):137-40. PubMed PMID: 11926558.

105: Sivridis E, Giatromanolaki A, Anastasiadis P, Georgiou L, Gatter KC, Harris AL, Bicknell R, KOUKOURAKIS MI; Tumor and Angiogenesis Research Group. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. *J Pathol*. 2002 Apr;196(4):416-22. PubMed PMID: 11920737.

106: Kakolyris S, Giatromanolaki A, KOUKOURAKIS M, Kaklamanis L, Kouroussis CH, Bozionelou V, Georgoulas V, Gatter KC, Harris AL. Assessment of vascular maturation in lung and breast carcinomas using a novel basement membrane component, LH39. *Anticancer Res*. 2001 Nov-Dec;21(6B):4311-6. PubMed PMID: 11908685.

107: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pissakas G, Gatter KC, Harris AL. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. *Anticancer Res*. 2001 Nov-Dec;21(6B):4301-9. PubMed PMID: 11908684.

108: Sivridis E, Giatromanolaki A, KOUKOURAKIS MI, Georgiou L, Anastasiadis P. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. *Histopathology*. 2002 Jan;40(1):92-100. PubMed PMID: 11903603.

109: Giatromanolaki A, Sivridis E, KOUKOURAKIS MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. *Am J Clin Oncol*. 2002 Feb;25(1):38-41. PubMed PMID: 11823693.

110: Giatromanolaki A, Sivridis E, Brekken R, Thorpe PE, Anastasiadis P, Gatter KC, Harris AL, KOUKOURAKIS MI; Tumor and Angiogenesis Research Group. The angiogenic

"vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. *Cancer*. 2001 Nov 15;92(10):2569-77. PubMed PMID: 11745191.

111: KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. *Clin Cancer Res*. 2001 Nov;7(11):3399-403. PubMed PMID: 11705854.

112: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. *Cancer Res*. 2001 Nov 1;61(21):7992-8. PubMed PMID: 11691824.

113: Kakolyris S, Giatromanolaki A, KOUKOURAKIS M, Powis G, Souglakos J, Sivridis E, Georgoulas V, Gatter KC, Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. *Clin Cancer Res*. 2001 Oct;7(10):3087-91. PubMed PMID: 11595699.

114: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. *Br J Cancer*. 2001 Sep 14;85(6):881-90. PubMed PMID: 11556841; PubMed Central PMCID: PMC2375073.

115: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Thorpe PE, Brekken RA, Konstantinos S, Fountzilas G, Gatter KC, Harris AL. Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. *Clin Exp Metastasis*. 2000;18(4):313-9. PubMed PMID: 11448062.

116: Papadopoulos I, Sivridis E, Giatromanolaki A, KOUKOURAKIS MI. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. *Clin Cancer Res*. 2001 Jun;7(6):1533-8. PubMed PMID: 11410487.

117: Giatromanolaki A, Stathopoulos GP, KOUKOURAKIS MI, Rigatos S, Vrettou E, Kittas C, Fountzilas G, Sivridis E. Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. *Am J Clin Oncol*. 2001 Jun;24(3):222-6. PubMed PMID: 11404489.

118: Sivridis E, Giatromanolaki A, KOUKOURAKIS M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. *Virchows Arch*. 2001 May;438(5):470-7. PubMed PMID: 11407475.

119: Kakolyris SA, Kaklamanis LG, KOUKOURAKIS MJ, Giatromanolaki A, Rousomoustakaki M, Souglakos JC, Reppa DK, Georgoulas VA, Gatter KC, Harris AL. Angiogenesis and p53 expression in the colorectal adenoma-carcinoma sequence. *Oncol Res*. 2000;12(4):203-8. PubMed PMID: 11341470.

120: Giatromanolaki A, Sivridis E, Athanassou N, Zois E, Thorpe PE, Brekken RA, Gatter KC, Harris AL, KOUKOURAKIS IM, KOUKOURAKIS MI. The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis. *J Pathol*. 2001 May;194(1):101-8. PubMed PMID: 11329148.

121: KOUKOURAKIS MI, Giatromanolaki A, Kakolyris S, Sivridis E, Georgoulas V, Fountzilas G, Hickson ID, Gatter KC, Harris AL. Nuclear expression of human apurinic/aprimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with

resistance to chemoradiotherapy and poor outcome. *Int J Radiat Oncol Biol Phys.* 2001 May 1;50(1):27-36. PubMed PMID: 11316543.

122: KOUKOURAKIS MI, Corti L, Skarlatos J, Giatromanolaki A, Krammer B, Blandamura S, Piazza M, Verwanger T, Schnitzhofer G, Kostandelos J, Beroukas K. Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy. *Anticancer Res.* 2001 Jan-Feb;21(1B):663-8. PubMed PMID: 11299823.

123: Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C, Polychronidis A, Simopoulos K, KOUKOURAKIS MI. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. *Anticancer Res.* 2001 Jan-Feb;21(1A):253-9. PubMed PMID:11299743.

124: KOUKOURAKIS MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. *Cancer Res.* 2001 Mar 1;61(5):1830-2. PubMed PMID: 11280732.

125: Kapsoritakis AN, KOUKOURAKIS MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA. Mean platelet volume: a useful marker of inflammatory bowel disease activity. *Am J Gastroenterol.* 2001 Mar;96(3):776-81. PubMed PMID: 11280550.

126: Kapsoritakis AN, Potamianos SP, Sfiridaki AI, KOUKOURAKIS MI, Koutroubakis IE, Roussomoustakaki MI, Manousos ON, Kouroumalis EA. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease. *Am J Gastroenterol.* 2000 Dec;95(12):3478-81. PubMed PMID: 11151880.

127: Giatromanolaki A, KOUKOURAKIS MI, Stathopoulos GP, Kapsoritakis A, Paspatis G, Kakolyris S, Sivridis E, Georgoulas V, Harris AL, Gatter KC. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. *Oncol Res.* 2000;12(1):33-41. PubMed PMID: 11061344.

128: Sivridis E, Giatromanolaki A, KOUKOURAKIS MI, Bicknell R, Harris AL, Gatter KC. Thymidine phosphorylase expression in normal and hyperplastic endometrium. *J Clin Pathol.* 2000 Sep;53(9):704-8. PubMed PMID: 11041061; PubMed Central PMCID: PMC1731246.

129: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, O'Byrne K, Gatter KC, Harris AL. 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. *J Pathol.* 2000 Oct;192(2):140-9. PubMed PMID: 11004689.

130: KOUKOURAKIS MI. Microvessel density, thymidine phosphorylase expression and resistance of head and neck cancer to chemo-radiotherapy. *Adv Exp Med Biol.* 2000;476:285-9. PubMed PMID: 10949672.

131: Kaklamanis L, Kakolyris S, KOUKOURAKIS M, Gatter KC, Harris AL. From hyperplasia to neoplasia and invasion: angiogenesis in the colorectal adenoma-carcinoma model. *Adv Exp Med Biol.* 2000;476:249-66. PubMed PMID: 10949670.

132: KOUKOURAKIS MI, Giatromanolaki A, Kakolyris S, Froudarakis M, Georgoulas V, Retalis G, Bahlitzanakis N. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. *Med Oncol.* 2000 May;17(2):135-43. PubMed PMID: 10871820.

133: KOUKOURAKIS MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, Harris AL. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. *Clin Exp Metastasis*. 1999;17(7):545-54. PubMed PMID: 10845553.

134: KOUKOURAKIS MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulas V, Gatter KC, Harris AL. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. *Cancer Res*. 2000 Jun 1;60(11):3088-95. PubMed PMID: 10850461.

135: Giatromanolaki A, Sivridis E, KOUKOURAKIS MI, Georgoulas V, Gatter KC, Harris AL. Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? *Oncol Res*. 1999;11(4):205-12. PubMed PMID: 10566619.

136: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, O'Byrne K, Cox G, Thorpe PE, Gatter KC, Harris AL. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. *Clin Cancer Res*. 2000 May;6(5):1917-21. PubMed PMID: 10815916.

137: Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Fountzilas G. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. *Anticancer Res*. 2000 Mar-Apr;20(2A):997-1004. PubMed PMID: 10810387.

138: O'Byrne KJ, KOUKOURAKIS MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. *Br J Cancer*. 2000 Apr;82(8):1427-32. PubMed PMID: 10780522; PubMed Central PMCID: PMC2363365.

139: Kakolyris S, Fox SB, KOUKOURAKIS M, Giatromanolaki A, Brown N, Leek RD, Taylor M, Leigh IM, Gatter KC, Harris AL. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. *Br J Cancer*. 2000 Feb;82(4):844-51. PubMed PMID: 10732757; PubMed Central PMCID: PMC2374391.

140: KOUKOURAKIS MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. *Clin Cancer Res*. 2000 Feb;6(2):381-9. PubMed PMID: 10690514.

141: KOUKOURAKIS MI, Giatromanolaki A, Guddo F, Kaklamanis L, Vignola M, Kakolyris S, Turley H, Georgoulas V, Bonsignore G, Gatter KC, Harris AL. c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. *J Immunother*. 2000 Jan;23(1):104-14. PubMed PMID: 10687143.

142: Sivridis E, Giatromanolaki A, KOUKOURAKIS M, Agnantis N. Lectin-binding patterns in normal, hyperplastic and neoplastic endometrium: the prognostic value of concanavalin A. *Virchows Arch*. 2000 Jan;436(1):52-8. PubMed PMID: 10664162.

143: Sivridis E, Giatromanolaki A, KOUKOURAKIS MI, Bicknell R, Harris AL, Gatter KC. Thymidine phosphorylase expression in endometrial carcinomas. *Clin Exp Metastasis*. 1999 Jul;17(5):445-50. PubMed PMID: 10651312.

- 144: Kakolyris S, Giatromanolaki A, KOUKOURAKIS M, Leigh IM, Georgoulas V, Kanavaros P, Sivridis E, Gatter KC, Harris AL. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. *Cancer Res.* 1999 Nov 1;59(21):5602-7. PubMed PMID: 10554041.
- 145: Kakolyris S, Giatromanolaki A, KOUKOURAKIS M, Kaklamanis L, Kanavaros P, Hickson ID, Barzilay G, Georgoulas V, Gatter KC, Harris AL. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). *J Pathol.* 1999 Nov;189(3):351-7. PubMed PMID: 10547596.
- 146: Giatromanolaki A, Stathopoulos GP, Tsiompanou E, Papadimitriou C, Georgoulas V, Gatter KC, Harris AL, KOUKOURAKIS MI. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. *Cancer.* 1999 Oct 15;86(8):1421-30. Erratum in: *Cancer.* 2009 Sept 1;115(17):4040. Tsiobanou, E [corrected to Tsiompanou, E]. PubMed PMID: 10526268.
- 147: Giatromanolaki A, KOUKOURAKIS MI, Georgoulas V, Gatter KC, Harris AL, Fountzilias G. Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. *Int J Cancer.* 1999 Mar 15;80(6):810-7. PubMed PMID: 10074911.
- 148: Giatromanolaki A, Fountzilias G, KOUKOURAKIS MI, Arapandoni P, Theologi V, Kakolyris S, Georgoulas V, Harris AL, Gatter KC. Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. *Clin Exp Metastasis.* 1998 Oct;16(7):665-72. PubMed PMID: 9932613.
- 149: Guddo F, Giatromanolaki A, KOUKOURAKIS MI, Reina C, Vignola AM, Chlouverakis G, Hilken J, Gatter KC, Harris AL, Bonsignore G. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. *J Clin Pathol.* 1998 Sep;51(9):667-71. PubMed PMID: 9930070; PubMed Central PMCID: PMC500903.
- 150: Giatromanolaki A, KOUKOURAKIS M, Zamboukas T, Skordalaki A, Arapantoni P, Georgoulas V, Fountzilias G. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. *Anticancer Res.* 1998 Nov-Dec;18(6B):4685-92. PubMed PMID: 9891541.
- 151: Kakolyris S, Kaklamanis L, Giatromanolaki A, KOUKOURAKIS M, Hickson ID, Barzilay G, Turley H, Leek RD, Kanavaros P, Georgoulas V, Gatter KC, Harris AL. Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human disease. *Histopathology.* 1998 Dec;33(6):561-9. PubMed PMID: 9870152.
- 152: Kakolyris S, Samonis G, KOUKOURAKIS M, Vlachonicolis J, Kalbakis K, Agelaki S, Chalkiadakis G, Sanidas E, Tsiftsis D, Georgoulas V. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormone therapy with tamoxifen and megestrol acetate in advanced breast cancer. *Am J Clin Oncol.* 1999 Jun;22(3):273-7. PubMed PMID: 10362335.
- 153: Arapandoni-Dadioti P, Giatromanolaki A, Trihia H, Harris AL, KOUKOURAKIS MI. Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. *Cancer Lett.* 1999 Apr 1;137(2):145-50. PubMed PMID: 10374835.

154: Giatromanolaki A, KOUKOURAKIS MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulis V, Harris AL, Gatter KC. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. *Clin Cancer Res.* 1998 Dec;4(12):3017-24. PubMed PMID: 9865915.

155: Giatromanolaki A, Sivridis E, KOUKOURAKIS MI, Harris AL, Gatter KC. Bcl-2 and p53 expression in stage I endometrial carcinoma. *Anticancer Res.* 1998 Sep-Oct;18(5B):3689-93. PubMed PMID: 9854478.

156: Giatromanolaki A, KOUKOURAKIS MI, Theodossiou D, Barbatis K, O'Byrne K, Harris AL, Gatter KC. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. *Clin Cancer Res.* 1997 Dec;3(12 Pt 1):2485-92. PubMed PMID: 9815651.

157: Guddo F, Giatromanolaki A, Patriarca C, Hilkens J, Reina C, Alfano RM, Vignola AM, KOUKOURAKIS MI, Gambacorta M, Pruneri G, Coggi G, Bonsignore G. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. *Anticancer Res.* 1998 May-Jun;18(3B):1915-20. PubMed PMID: 9677444.

158: KOUKOURAKIS MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J, Gatter KC, Harris AL. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. *Br J Cancer.* 1998 May;77(10):1696-703. PubMed PMID: 9635852; PubMed Central PMCID: PMC2150048.

159: Giatromanolaki A, KOUKOURAKIS MI, Kakolyris S, Kaklamanis L, Barbatis K, O'Byrne KJ, Theodossiou D, Harris AL, Gatter KC. Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neoangiogenesis in non-small cell lung cancer. *Anticancer Res.* 1998 Jan-Feb;18(1A):71-6. PubMed PMID: 9568058.

160: Giatromanolaki A, KOUKOURAKIS MI. p53 and angiogenesis in non-small-cell lung cancer. *Br J Cancer.* 1998 Mar;77(5):850-2. PubMed PMID: 9514069; PubMed Central PMCID: PMC2149961.

161: KOUKOURAKIS MI, Giatromanolaki A, O'Byrne KJ, Whitehouse RM, Talbot DC, Gatter KC, Harris AL. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. *Int J Cancer.* 1997 Dec 19;74(6):565-70. PubMed PMID: 9421349.

162: Giatromanolaki A, KOUKOURAKIS MI, Comley M, Kaklamanis L, Turley H, O'Byrne K, Harris AL, Gatter KC. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. *J Pathol.* 1997 Feb;181(2):196-9. PubMed PMID: 9120725.

163: KOUKOURAKIS MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. *Br J Cancer.* 1997;75(4):477-81. PubMed PMID: 9052396; PubMed Central PMCID: PMC2063312.

164: Giatromanolaki A, KOUKOURAKIS MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. *Anticancer Res.* 1996 Nov-Dec;16(6B):3819-25. PubMed PMID: 9042264.

165: Kaklamanis L, KOUKOURAKIS MI, Leek R, Giatromanolaki A, Ritter M, Whitehouse R, Gatter KC, Harris AL. Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance. *Br J Cancer*. 1996 Nov;74(10):1627-31. PubMed PMID: 8932345; PubMed Central PMCID: PMC2074844.

166: Giatromanolaki A, Gorgoulis V, Chetty R, KOUKOURAKIS MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC, Iordanoglou I. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. *Anticancer Res*. 1996 Mar-Apr;16(2):987-93. PubMed PMID: 8687165.

167: Kaklamanis L, Leek R, KOUKOURAKIS M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. *Cancer Res*. 1995 Nov 15;55(22):5191-4. PubMed PMID: 7585572.

168: Giatromanolaki A, KOUKOURAKIS M, O'Byrne K, Fox S, Whitehouse R, Talbot DC, Harris AL, Gatter KC. Prognostic value of angiogenesis in operable non-small cell lung cancer. *J Pathol*. 1996 May;179(1):80-8. PubMed PMID: 8691350.

EXPERIMENTAL (13)

1: Koukourakis MI, Kalamida D, Giatromanolaki A, Zois CE, Sivridis E, Pouliliou S, Mitrakas A, Gatter KC, Harris AL. Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines. *PLoS One*. 2015 Sep 17;10(9):e0137675.

2: Kalamida D, Karagounis IV, Mitrakas A, Kalamida S, Giatromanolaki A, KOUKOURAKIS MI. Fever-range hyperthermia vs. hypothermia effect on cancer cell viability, proliferation and HSP90 expression. *PLoS One*. 2015 Jan 30;10(1):e0116021. doi: 10.1371/journal.pone.0116021. eCollection 2015. PubMed PMID: 25635828; PubMed Central PMCID: PMC4312095.

3: Mitrakas AG, Kalamida D, KOUKOURAKIS MI. Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity. *Anticancer Drugs*. 2014 Nov;25(10):1182-91. doi: 10.1097/CAD.000000000000152. PubMed PMID: 25035963.

4: Kalamida D, Karagounis IV, Giatromanolaki A, KOUKOURAKIS MI. Important role of autophagy in endothelial cell response to ionizing radiation. *PLoS One*. 2014 Jul 10;9(7):e102408. doi: 10.1371/journal.pone.0102408. eCollection 2014. PubMed PMID: 25010689; PubMed Central PMCID: PMC4092133.

5: Zachari MA, Chondrou PS, Pouliliou SE, Mitrakas AG, Abatzoglou I, Zois CE, KOUKOURAKIS MI. Evaluation of the alamarblue assay for adherent cell irradiation experiments. *Dose Response*. 2013 Sep 12;12(2):246-58. doi: 10.2203/dose-response.13-024.KOUKOURAKIS. eCollection 2014 May. PubMed PMID:

6: Abatzoglou I, Zois CE, Pouliliou S, KOUKOURAKIS MI. Establishment and validation of a method for multi-dose irradiation of cells in 96-well microplates. *Biochem Biophys Res Commun*. 2013 Feb 15;431(3):456-9. doi: 10.1016/j.bbrc.2012.12.146. Epub 2013 Jan 16. PubMed PMID: 23333388.

7: Klionsky DJ, ... KOUKOURAKIS MI,.....et al Guidelines for the use and interpretation of assays for monitoring autophagy *Autophagy*. 2012 Apr;8(4):445-544. PubMed PMID: 22966490; PubMed Central PMCID: PMC3404883.

8: Zois CE, Giatromanolaki A, Sivridis E, Papaiakevou M, Kainulainen H, KOUKOURAKIS MI. "Autophagic flux" in normal mouse tissues: focus on endogenous LC3A processing. *Autophagy*. 2011 Nov;7(11):1371-8. doi: 10.4161/auto.7.11.16664. Epub 2011 Nov 1. PubMed PMID: 21997374.

9: Zois CE, Giatromanolaki A, Sivridis E, Tokmakidis SP, Botaitis S, Simopoulos C, Kortsaris A, KOUKOURAKIS MI. Narrow amifostine dose windows define radioprotection outcome, following fractionated whole-body irradiation of mice. *In Vivo*. 2011 Mar-Apr;25(2):191-6. PubMed PMID: 21471534.

10: Zois CE, Giatromanolaki A, Kainulainen H, Botaitis S, Torvinen S, Simopoulos C, Kortsaris A, Sivridis E, KOUKOURAKIS MI. Lung autophagic response following exposure of mice to whole body irradiation, with and without amifostine. *Biochem Biophys Res Commun*. 2011 Jan 7;404(1):552-8. doi: 10.1016/j.bbrc.2010.12.024. Epub 2010 Dec 8. PubMed PMID: 21145309.

11: Lialiaris TS, Kotsiou E, Pouliliou S, Kareli D, Makrinou H, Kouskoukis A, Papachristou F, KOUKOURAKIS M. Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan. *Food Chem Toxicol*. 2009 Oct;47(10):2445-9. doi: 10.1016/j.fct.2009.06.042. Epub 2009 Jul 3. PubMed PMID: 19577607.

12: Zois CE, KOUKOURAKIS MI. Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-sensitization policies? *Autophagy*. 2009 May;5(4):442-50. Epub 2009 May 19. Review. PubMed PMID: 19164950.

13: Bayele HK, Peyssonnaud C, Giatromanolaki A, Arrais-Silva WW, Mohamed HS, Collins H, Giorgio S, KOUKOURAKIS M, Johnson RS, Blackwell JM, Nizet V, Srai SK. HIF-1 regulates heritable variation and allele expression phenotypes of the macrophage immune response gene SLC11A1 from a Z-DNA forming microsatellite. *Blood*. 2007 Oct 15;110(8):3039-48. Epub 2007 Jul 2. PubMed PMID: 17606764.

REVIEWS (23)

1: Kontomanolis EN, KOUKOURAKIS MI. MicroRNA: The Potential Regulator of Endometrial Carcinogenesis. *Microna*. 2015;4(1):18-25. PubMed PMID: 26088599.

2: Pouliliou S, KOUKOURAKIS MI. Gamma histone 2AX (γ -H2AX) as a predictive tool in radiation oncology. *Biomarkers*. 2014 May;19(3):167-80. doi: 10.3109/1354750X.2014.898099. Epub 2014 Mar 10. Review. PubMed PMID: 24611829.

3: KOUKOURAKIS MI. Radiation damage and radioprotectants: new concepts in the era of molecular medicine. *Br J Radiol*. 2012 Apr;85(1012):313-30. doi: 10.1259/bjr/16386034. Epub 2012 Jan 31. PubMed PMID: 22294702; PubMed Central PMCID: PMC3486665.

4: Kyrgias G, Theodorou K, Zygogianni A, Tsanadis K, Zervoudis S, Tzitzikas J, KOUKOURAKIS M. Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature. *Breast Cancer (Dove Med Press)*. 2012 Jan 24;4:3-8. doi: 10.2147/BCTT.S28412. eCollection 2012. PubMed PMID: 24367188; PubMed Central PMCID: PMC3846919.

- 5: KOUKOURAKIS G, Kouloulis V, Zacharias G, Sotiropoulou-Lontou A, KOUKOURAKIS M. Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review. *Clin Transl Oncol*. 2011 May;13(5):315-21. doi: 10.1007/s12094-011-0660-7. Review. PubMed PMID: 21596659.
- 6: Skarlatos I, Kyrgias G, Mosa E, Provatopoulou X, Spyrou M, Theodorou K, Lepouras A, Gounaris A, KOUKOURAKIS M. Electrochemotherapy in cancer patients: first clinical trial in Greece. *In Vivo*. 2011 Mar-Apr;25(2):265-74. PubMed PMID: 21471545.
- 7: KOUKOURAKIS G, Kouloulis V, Zacharias G, KOUKOURAKIS M. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy. *J BUON*. 2010 Oct-Dec;15(4):652-9. PubMed PMID: 21229625.
- 8: Tsoutsou PG, Belkacemi Y, Gligorov J, Kuten A, Boussen H, Bese N, KOUKOURAKIS MI; Association of Radiotherapy and Oncology in the Mediterranean area (AROME). Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. *Oncologist*. 2010;15(11):1169-78. doi: 10.1634/theoncologist.2010-0187. Epub 2010 Nov 1. PubMed PMID: 21041378; PubMed Central PMCID: PMC3227907.
- 9: KOUKOURAKIS GV, Zabatis H, Zacharias GA, KOUKOURAKIS MJ. Post-surgical irradiation causes cellular immune suppression in patients with breast cancer. *Eur J Cancer Care (Engl)*. 2009 May;18(3):306-12. PubMed PMID: 19445021.
- 10: KOUKOURAKIS G, Zacharias G, KOUKOURAKIS M, Pistevou-Gobaki K, Papaloukas C, Kostakopoulos A, Kouloulis V. Comprehensive management of upper tract urothelial carcinoma. *Adv Urol*. 2009;656521. doi: 10.1155/2009/656521. Epub 2008 Dec 10. PubMed PMID: 19096525; PubMed Central PMCID: PMC2600411.
- 11: Tsoutsou PG, KOUKOURAKIS MI, Azria D, Belkacémi Y. Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. *Crit Rev Oncol Hematol*. 2009 Aug;71(2):102-16. doi: 10.1016/j.critrevonc.2008.09.002. Epub 2008 Oct 14. Review. PubMed PMID: 18922700.
- 12: Giatromanolaki A, Sivridis E, KOUKOURAKIS MI. The pathology of tumor stromatogenesis. *Cancer Biol Ther*. 2007;6(5):639-45. Epub 2007 May 30. PubMed PMID: 17534144.
- 13: Tsoutsou PG, KOUKOURAKIS MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. *Int J Radiat Oncol Biol Phys*. 2006 Dec 1;66(5):1281-93. Review. PubMed PMID: 17126203.
- 14: Giatromanolaki A, Sivridis E, KOUKOURAKIS MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. *Am J Clin Oncol*. 2006 Aug;29(4):408-17. Review. PubMed PMID: 16891872.
- 15: KOUKOURAKIS MI, Danielidis V. Preventing radiation induced xerostomia. *Cancer Treat Rev*. 2005 Nov;31(7):546-54. Epub 2005 Oct 26. Review. PubMed PMID: 16257125.
- 16: Giatromanolaki A, Sivridis E, KOUKOURAKIS MI. Tumour angiogenesis: vascular growth and survival. *APMIS*. 2004 Jul-Aug;112(7-8):431-40. Review. PubMed PMID: 15563307.
- 17: Sivridis E, Giatromanolaki A, KOUKOURAKIS MI. "Stromatogenesis" and tumor progression. *Int J Surg Pathol*. 2004 Jan;12(1):1-9. PubMed PMID: 14765266.

- 18: KOUKOURAKIS MI. Amifostine: is there evidence of tumor protection? *Semin Oncol.* 2003 Dec;30(6 Suppl 18):18-30. Review. PubMed PMID: 14727237.
- 19: Sivridis E, Giatromanolaki A, KOUKOURAKIS MI. The vascular network of tumours--what is it not for? *J Pathol.* 2003 Oct;201(2):173-80. Review. PubMed PMID: 14517833.
- 20: KOUKOURAKIS MI. Amifostine in clinical oncology: current use and future applications. *Anticancer Drugs.* 2002 Mar;13(3):181-209. Review. PubMed PMID: 11984063.
- 21: KOUKOURAKIS M. [Management of non-small-cell lung carcinoma (NSCLC) of stage III B]. *Rev Pneumol Clin.* 2001 Nov;57(5 Pt 2):S33-6. Review. French. PubMed PMID: 11924241.
- 22: KOUKOURAKIS MI. Tumour angiogenesis and response to radiotherapy. *Anticancer Res.* 2001 Nov-Dec;21(6B):4285-300. Review. PubMed PMID: 11908683.
- 23: O'Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, KOUKOURAKIS MI, Giatromanolaki A, Gatter K, Harris AL, Waller D, Jones JL. Towards a biological staging model for operable non small cell lung cancer. *Lung Cancer.* 2001 Dec;34 Suppl 2:S83-9. PubMed PMID: 11720747.

16. ABSTRACTS PRESENTED IN INTERNATIONAL CONGRESSES

(98 abstracts)

Published in Journals

1. D. Kalamida, MI KOUKOURAKIS. Transcription factor EB (TFEB) sustains the migratory phenotype of lung cancer cell lines. **9th International Conference of Anticancer Research**, Sithonia, 6-10 October, 2014. *Anticancer Research* 2014; 34:5983
2. I.V. Karagounis, D. Kalamida, AG Mitrakas, MV Liouisia, A. Giatromanolaki, MI KOUKOURAKIS, In vitro characterization of autophagy flux after exposure to ionizing radiation in Lung cancer. **9th International Conference of Anticancer Research, Sithonia, 6-10 October, 2014**. *Anticancer Research* 2014; 34:5986-87
3. MI KOUKOURAKIS. LC3A vs. LC3B. Two distinct autophagosome markers to consider for experimental and translational studies. **9th International Conference of Anticancer Research, Sithonia, 6-10 October, 2014**. *Anticancer Research* 2014; 34:6005
4. AG Mitrakas, D. Kalamida, IV Karagounis, S. Pouliliou, A Giatromanolaki, MI KOUKOURAKIS. Silencing of LC3 autophagy proteins sensitizes glioblastoma cell lines to radiation. **9th International Conference of Anticancer Research, Sithonia, 6-10 October, 2014**. *Anticancer Research* 2014; 34:6062-6063
5. S Pouliliou, D. Kalamida, MI KOUKOURAKIS. A γ H2AX study in mouse liver NCTC cells following irradiation (with and without amifostine). **9th International Conference of Anticancer Research, Sithonia, 6-10 October, 2014**. *Anticancer Research* 2014; 34:6119
6. Spyridopoulou K, Tiptiri-Kourpeti A, Simeonidis K, KOUKOURAKIS MI, Kalogirou O, Chlichlia K. Optimization of a syngeneic mouse tumor model with magnetic nanoparticles for pre-clinical screening of new anticancer agents. **9th International Conference of Anticancer Research, Sithonia, 6-10 October, 2014**. *Anticancer Research* 2014; 34:6184
7. MI KOUKOURAKIS, D Kalamida, I. Karagounis, A. Giatromanolaki. Autophago-lysosomal flux following exposure of endothelial cells and fibroblasts to ionizing radiation. **ASTRO 2014 Annual Meeting**, San Francisco, USA. *Proceeding of the American Society for Radiation Oncology. Int J Radiat Oncol Biol Phys* 2014;90:Abstr 3423.
8. Theodoropoulou A, Kostantinidis K, Tribonias G, Vardas E, Ieromonachou P, Zois E, Koukourakis M, Giatromanolaki A, Sivridis E, Paspatis G. Expression of factors induced under hypoxic conditions (hypoxia inducible factors HIF1a/HIF2a) in patients with Crohn's disease and ischemic colitis. **4th European Crohn's and Colitis Organization Congress**. Hamburg, Germany, February 5-7, 2009.
9. P.G. Tsoutsou, V. Danielidis, M.I. KOUKOURAKIS. Cetuximab, cisplatin and amifostine during accelerated radiotherapy for locally advanced head and neck cancer. *J Clin Oncol (suppl)* 27. Presented at the **American Society of Clinical Oncology Annual Meeting**, USA, 2008
10. M. I. KOUKOURAKIS, P. G. Tsoutsou, M. Pitiakoudis, G. Kouklakis, N. Liratzopoulos, A. Polyhronidis, I. Abatzoglou, C. Simopoulos, K. Manolas. Bevacizumab-based conformal radio-chemotherapy for locally advanced inoperable colorectal cancer. *J Clin Oncol (suppl)* 27. Presented at the **American Society of Clinical Oncology Annual Meeting**, USA, 2008
11. KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL, Trarbach T, Folprecht G, Meinhardt G. Intratumoral lactate dehydrogenase 5 (LDH5) protein is associated with the expression of angiogenesis markers and hypoxia in patients with colorectal cancer. **J Clin Oncol (suppl) Vol 25, N018S, Part I, Abstr. 4107, 2007** Presented at the **American Society of Clinical Oncology Annual Meeting**, USA
12. Giatromanolaki A, KOUKOURAKIS MI, Harris AL, Gatter KC, Stamos H, Sivridis E. Expression of phosphorylated (activated) receptors of vascular endothelial growth factor (VEGFR2/KDR) in colorectal cancer. **Virchows Archiv**, abstr. **PP1-80, 451: 218, 2007** Presented at the European Congress of Pathology, Istanbul, Turkey, September 2007
13. KOUKOURAKIS MI, Giatromanolaki A, Stamos H, Danielidis V, Sivridis E. Hypoxia Inducible factors HIF1a and HIF2a are linked to poor response of head-neck cancer to radiotherapy. **Virchows Archiv**, abstr. **OP27-3, 451: 182, 2007**. Presented at the European Congress of Pathology, Istanbul, Turkey, September 2007

14. Giatromanolaki A, Charalambidis CH., KOUKOURAKIS MI, Sivridis E. Tumor hypoxia and acidity drive stromatogenesis at the invading tumor edge of colorectal carcinomas. **Virchows Archiv**, **abstr. 2005**. Presented at the 20th European Congress of Pathology, Paris, France, Septemeber 2005
15. Giatromanolaki A, Sivridis E, KOUKOURAKIS MI, Ritis C, Mimidis C, Kartalis G. Interferon Regulatory Factor 1 (IRF-1) suppression and derepression in endometrial carcinomas. **Virchows Archiv**, **abstr. 075, pp 269, 2003**. Presented at the European Congress of Pathology, Lubliana, Slovenia, Septemeber 2003
16. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, KOUKOURAKIS MI. Hypoxia-inducible factors 1a and 2a in skin malignant melanomas. **Eur J Cancer (suppl 252); abstr. 835, 2003**. Presented at the European Cancer Conference (ECCO 12), Copenhagen, Denmark, Septemeber 2003
17. Boccia RV, Bouhris J, Brizel D, Daly C, Hollowy N, Hymes S, KOUKOURAKIS MI, Turner M, Wasserman T. Management of cutaneous reactions associated with amifostine: Findings of an independent panel. **Proc of ASCO, Volume 22, abstr. 3175, 2003**. Presented at the American Society of Clinical Oncology Annual Mmeting, Chicago, Illinois, USA
18. KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, Boujoukas G, Gatter KC, Harris AL. Differential expression of carbonic anhydrase and of hypoxia inducible factors in non-small cell lung cancer. **Radiotherapy and Oncology 2002 supplement**. Presented at the ESTRO Congress, Prague, 2002
19. Giatromanolaki A, Romanidis K, Sivridis E, Manolas C, Simopoulos C, Polychronidis A, Minopoulos G, Lirazopoulos N, Pitiakoudis M, KOUKOURAKIS MI. Tumor angiogenesis and relapse in operable breast cancer. **European Journal of Surgical Oncology 2002; 28(3): 338**. Presented at the European Congress of Surgical Oncology, 17-20 April, Lille, France, 2002
20. Giatromanolaki A, E. Sivridis, KC Gatter, AL Harris, G Bougioukas, MI KOUKOURAKIS. Patterns of expression of three hypoxia regulated proteins (HIF1a, HIF2a and Carbonic Anhydrase CA9) in squamous cell carcinoma of the lung. **Virchows Archiv 2001; 439: 349**. Presented at the 18th European Congress of Pathology, Berlin, September 8-13, 2001
21. Sivridis E, Giatromanolaki A, MI KOUKOURAKIS, Georgiou L, Galazios G, Anastasiadis P. MUC1 expresssion correlates with poor prognosis in endometrial carcinomas. **Virchows Archiv 2001; 439: 247**. Presented at the 18th European Congress of Pathology, Berlin September 8-13, 2001
22. MI KOUKOURAKIS, A Giatromanolaki, E. Kontoleon, K. Triantafilides, E. Sivridis. Loss of alkaline phosphatase expression in breast carcinoma: implications in the amifostine selective cytoprotection. **Eur J Cancer 2001; 37: S200**. Presented at the ECCO1, Lisbon October 21-25
23. A.Giatromanolaki, E. Sivridis, KC Gatter, AL Harris, G Bougioukas, MI KOUKOURAKIS. Patterns of expression of three hypoxia regulated proteins (HIF1a, HIF2a and Carbonic Anhydrase CA9) in squamous cell carcinoma of the lung. **Eur J Cancer 2001**. Presented at the: ECCO11, Lisbon October 21-25
24. E. Sivridis, A.Giatromanolaki, MI KOUKOURAKIS, L.Georgiou, G.Galazios, P. Anastasiadis. MUC1 expresssion correlates with poor prognosis in endometrial carcinomas. **Virchows Archiv 439: 247, 2001**
25. KOUKOURAKIS MI, Yannakakis D. Hypofractionated and accelerated radiotherapy with Ethyol cytoprotection (HypoARC) forlocally advanced breast cancer. **Proc Am Soc Clin Oncol 2001; 20:35b Abstr #1886**. Presented at the : **37th Annual Meeting of the ASCO, San Francisco, USA, May 12-15, 2001**
26. Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Gatter KC, Harris AL. Up-regulation of angiogenesis and of the angiogenic factor thymidine phosphorylase is involved in cancer regeneration during radiotherapy for head and neck cancer: implications in the therapeutic outcome. **Patologia 38:M39,#135, 2000**. Presented at the: **1st Intercontinental Congress of Pathology, Madeira, Portugal, April 30-May 6, 2000**
27. KOUKOURAKIS MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Gatter KC, Harris AL. Antibodies to occupied VEGF receptro (VEGF/KDR complex) show neo-vascularization in the stroma of non-small cell lung cancer which correlates with VEGF expression by fibroblasts and CD31+ lymphocytic infiltration. **Proc Am Assoc Cancer Res 2000, #558, pp87**. Presented at the : AACR Congress, San Francisco, April 1-5,
28. A Giatromanolaki, GP Stathopoulos, MI KOUKOURAKIS et al. Prognostic role of angiogenesis in colorectal cancer. **Proc Am Soc Clin Oncol 1999**, Presented at the : **35th ASCO Annual Meeting, Atlanta USA, 1999**
29. Giatromanolaki A, Schiza SE, KOUKOURAKIS MI et al. **American Journal of Respiratory and Critical Care Medicine, 159: A209, 1999**. Presented at the : 1999 International Conference, American Thoracic Society, San Diego, USA 1999

30. Kapsoritakis A, Potamianos S, KOUKOURAKIS MI et al. Thrombopoietin serum levels in patients with inflammatory bowel disease. **Gastroenterology** 1999; 116: G3235. Presented at the : 100th Annual meeting of the American Gastroenterological Association, Orlando, FL, USA, May 1999
31. Sivridis E, Giatromanolaki A, KOUKOURAKIS MI, Harris AL, Gatter KC. Patterns of thymidine phosphatase expression in endometrial carcinomas. *Virchows Arch* 1999; 435 (3):185. Presented at the : EUROPAE , Barcelona, Spain 9/1999
32. KOUKOURAKIS MI, Frangiadaki C, Stavroulaki A, Retalis G. Subcutaneous amifostine during fractionated radiotherapy: A randomized phase II study in pelvic tumours. **Eur J Cancer** 35(Suppl 4); 1999. Presented at the: ECCO 10, Vienna, 9/1999
33. KOUKOURAKIS MI, Chaldeopoulos D, Lyrarakis E, varveris Ch. Concurrent radiotherapy and chemotherapy with topotecan and stealth liposomal doxorubicin for the treatment of locally advanced pelvic tumours. **Eur J Cancer** 35(Suppl 4); 1999. Presented at the: ECCO 10, Vienna, 9/1999
34. Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, O;Byrne K, Gatter KC, Harris AL. Invading edge vs. inner vascularisation: angio-genic and angio-preserving activity in non-small cell lung cancer. **Eur J Cancer** 35(Suppl 4); 1999. Presented at the: ECCO 10, Vienna, 9/1999
35. Kapsoritakis A, Potamianos S, KOUKOURAKIS MI et al. Mean platelet volume as an indicator of activity in inflammatory bowel disease. **GUT** 1999; 31(suppl 1): 282. Presented at the: 7th UEGW, Rome, 1999
36. KOUKOURAKIS MI, Kakolyris S, Kouroussis C, Frangiadaki C, Garedaki E, Giatromanolaki A, Georgoulas V, Retalis G. Subcutaneous amifostine during fractionated radiotherapy for lung, pelvic and head and neck cancer. A randomized phase II study. **Int J Radiat Oncol Biol Phys** 1999; 45(Suppl), Abstr 177. Presented at the: 41st meeting Amer Soc Therap Radiol Oncol (ASTRO), San Antonio, Texas, USA.
37. Giatromanolaki A, Trichia E, KOUKOURAKIS M, Arapantoni-Dadioti P. Angiogenesis in ductal breast carcinoma: comparison of microvessel score between primary tumour and metastasis to the lymph-nodes. **Anticancer Res** 1998; 17:3845. Presented at the : 22nd International breast cancer research congress of the IABCR, 1998 Athens
38. Giatromanolaki A, KOUKOURAKIS M, Kakolyris S, Georgoulas V, Fountzilias G. p53, bcl2 and response of locally advanced squamous cell head and neck cancer to platinum based chemotherapy and chemo-radiotherapy. **Eur J Cancer** 1998; 34 (Suppl 2): 32. Presented at the: 3rd Educational Convention of the ESO, Turin, Italy, 28-30 May, 1998
39. KOUKOURAKIS M, Giatromanolaki A, Kakolyris S, Georgoulas V. Concurrent weekly docetaxel and radiotherapy for non-small cell lung cancer. A phase I and II trial with immunological toxicity evaluation. **Eur J Cancer** 1998; 34 (Suppl 2): 29 Presented at the: 3rd Educational Convention of the ESO, Turin, Italy, 28-30 May, 1998
40. Kakolyris S, Giatromanolaki A, KOUKOURAKIS M, Georgoulas V, Gatter KC, Harris AL. Human AP endonuclease 1 (HAP1) nuclear expression correlates with survival in operable non-small cell lung cancer. **Eur J Cancer** 1998; 34 (Suppl 2): 29 Presented at the: 3rd Educational Convention of the ESO, Turin, Italy, 28-30 May, 1998
41. O;Byrne K, Giatromanolaki A, KOUKOURAKIS M, Turley H, Scott PAE, Pezzella F, Harris AL, Gatter KC. Vascular endothelial growth factor expression in lung cancer. **British Journal of Cancer** 1998 (Suppl 1); 78:47. Presented at the : Joint British Association and Irish Association Cancer Research Meeting. Dublin 21-24 June , 1998
42. O;Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, KOUKOURAKIS MI, Talbot DC, Schally AV, Harris AL. The octapeptide somatostatin analogue RC160 suppresses IGF1 and elevated prolactin levels in breast cancer patients. **British Journal of Cancer** 1998 (Suppl 1); 78:53 Presented at the : Joint British Association and Irish Association Cancer Research Meeting. Dublin 21-24 June , 1998
43. Boso C, Corti L, Skarlatos J, KOUKOURAKIS M, Sotti C. La terapia fotodinamica in gastroenterologia **Radiol Medica** 95: abs 128; 1998. Presented at the : Congresso Nazionale 38o SIRM, Milano 1998
44. Koukouraki S, KOUKOURAKIS M, Perisinakis K, Giatromanolaki A, Manousakas I, Karkavitsas N. Functional imaging of non-small cell lung cancer with Tcsestamibi predicts response to chemotherapy and radiotherapy. **Eur J Nuclear Medicine** 1998; 25:867. Presented at the : International Congress of Nuclear Medicine, Berlin, August 1998;
45. Giatromanolaki A, Schiza S, KOUKOURAKIS MI et al Vascular endothelial growth factor (VEGF) and angiogenesis in non-small cell lung cancer. **European Respiratory Journal**, 1998; 12 (suppl28): 753 Presented at the : ERS Annual Congress, Geneva, Switzerland, Sept 19-23; 1998.
46. Giatromanolaki A, KOUKOURAKIS MI, Sivridis E, Gatter KC, Harris AL, Fountzilias G. The role of angiogenesis in the radiotherapy outcome of head and neck cancer. **Anticancer Res** 18:4869; 1998. Presented at the : 6th International Conference of Anticancer Research, Halkidiki, 1998

47. KOUKOURAKIS MI, Giatromanolaki A, Sivridis E, O'Byrne K, Kakolyris S, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase and vascular endothelial growth factor in non-small cell lung carcinoma. **Anticancer Res** **18:4869; 1998**. Presented at the : 6th International Conference of Anticancer Research, Halkidiki, 1998
48. KOUKOURAKIS M, Giatromanolaki A, Sivridis E et al. The role of angiogenesis in the chemoradiotherapy outcome of squamous cell head and neck cancer. **Radiother Oncol** **1998; 48(Suppl1): 640** Presented at the: ESTRO 17th annual meeting 1998, Edinburgh, UK
49. Giatromanolaki A, KOUKOURAKIS MI, et al. p53, bcl-2 and radiotherapy for locally advanced head and neck cancer. **Radiother Oncol** **1998; 48(Suppl1): 277**. Presented at the: ESTRO 17th annual meeting 1998, Edinburgh, UK
50. KOUKOURAKIS M. Weekly docetaxel combined with accelerated or conventionally fractionated radiotherapy for NSCLC. Results of phase I/II and II studies. **Radiother Oncol** **1998; 48(suppl1): #138** Presented at the: ESTRO 17th annual meeting 1998, Edinburgh, UK
51. KOUKOURAKIS MI, Giatromanolaki A, Koukouraki S, Divridis E, et al. Patterns of non-small cell lung cancer vascularisation. Potential role in radiosensitisation and radioprotection. **Radiotherapy Oncology** **1998; 48(Suppl1): #139** . Presented at the: ESTRO 17th annual meeting 1998, Edinburgh, UK
52. Giatromanolaki A, KOUKOURAKIS M, Harris AL, Gatter KC. Focal thymidine phosphorylase expression triggers local neo-angiogenesis in non small cell lung cancer. **Pathology Research and Practice** **193/5-6, 1997** Presented at the: XVI European Congress of Pathology, 31 September, Maastricht, 1997
53. KOUKOURAKIS M, Koukroussis C, Androulakis N, Kakolyris S, Georgoulas V. Accelerated radiotherapy and weekly docetaxel in non small cell lung cancer: a phase I/II study. **ASCO Proceedings, Vol 16 ; 1997 pp472**. Presented at the : ASCO Congress, USA, 1997
54. Giatromanolaki A, KOUKOURAKIS M, et al. Focal expression of platelet derived endothelial cell growth factor (PD-ECGF) triggers local neoangiogenesis in non-small cell lung cancer. **Eur J Cancer Vol 33 (Suppl 8) 1997, abstract 189** Presented at the : The European Cancer Conference ECCO-9, Hamburg , September 1997
55. Koukouraki S, KOUKOURAKIS M, Giatromanolaki A, Kapsoritakis A, Karkavitsas N. 99m-Tc-sestamibi extrusion rate correlates with resistance to cytotoxic treatment and distant metastasis in non-small cell lung cancer. **Eur J Cancer Vol 33 (Suppl 8), 1997, abstract 1043**. Presented at the : The European Cancer Conference ECCO-9, Hamburg , September 1997
56. K J O'Byrne , . KOUKOURAKIS MI, A Giatromanolaki, , K C. Gatter, A L Harris. bcl-2 oncoprotein suppresses angiogenesis by pd-ecgf down-regulation in non-small cell lung cancer. **Lung Cancer (Int Lung Cancer Congress , Dublin, 1997)**
57. A.Kapsoritakis, S. Potamianos, G. Alexandrakis, KOUKOURAKIS MI, M.Rousomoustakaki, M.Tzardi, E.Kouroumalis. Diminutive polyps of the large bowel should be an early target for endoscopic treatment. **GUT (suppl3) vol 41, pp29,1997 and Endoscopy 29:29, 1997**. Presented at the: 6th UEGW, UK Birmingham 1997.
58. KJ O'Byrne, KOUKOURAKIS MI, A Giatromanolaki, R Whitehouse, DC Talbot, KC Gatter, AL Harris. Correlation of bcl-2 expression with tumour angiogenesis in non-small cell lung cancer. **ASCO proceeding vol 15, 1146, 1996**. Presented at the : 32nd annual meeting , American Society of Clinical Oncology, USA May 18-21,1996
59. Varveris H, Fragiadaki C, Zolindaki A, KOUKOURAKIS M et al. Hyperfractionated or accelerated radiotherapy for tumors of the head and neck area. **Int J Oncol** **1995; 7(Suppl):963**
60. Varveris C, KOUKOURAKIS M., et al. External radiotherapy for inoperable colorectal cancer: analysis of 86 cases. **Br J Radiol** **66(Supl):109,1993** Presented at the : 51st annual Congress of the British Institute of Radiology, 1993 Glasgow, UK.

Published in the proceedings of congresses

61. Zois CE, Singleton D, Giatromanolaki A, Sivridis E, Morten K, Roxanis I, Leek R, **Koukourakis MI**, Harris AL. Autophagy in breast cancer in normoxia and hypoxia: distinct characteristics between HER2 positive and HER2 negative cell lines. EMBO Conference. Autophagy: molecular mechanism, physiology and pathology. **Hurtigruten MS Trollfjord, NORWAY 5-9 May 2013**
62. Karpathiou G, Mihailidis A, Giatromanolaki A, **Koukourakis M**, Steriopulos E, Sivridis E, Bouros D, Froudarakis M. Serial transbronchial biopsies in patients with lung cancer after radiation therapy. **European Respiratory Society, Amsterdam September 2011**

63. M Froudarakis, G Karpathiou, V. Mihailidis, A Giatromanolaki, **M Koukourakis**, G Kouliatsis, P Stipopoulos, E Sivridis, D Bouros. Transbronchial biopsy is able to monitor lung damage in lung cancer patients after radiation therapy. **1st European Congress for Bronchology and Interventional Pulmonology. March 10-12, 2011. Marceille France. Abstr. 01-041**
64. Zois CE, Giatromanolaki A, Kainulainen H, Botatitits S, Torvinen S, Simopoulos C, Kortsaris A, Sivridis E, Koukourakis MI. Radiation induced LC3A protein in normal lung tissue: intensified or aberrant autophagy ? **7th European Workshop on Cell Death. June27-July 2, 2010; abtr. No 19.**
65. A. Karpouzis, E. Sivridis, A. Bounovas, **M. Koukourakis**, C. Kouskoukis, A. Giatromanolaki. Malignant fibrous histiocytoma of the scalp. **18th congress of the European Academy of Dermatology and Venereology, Berlin October 7-11, 2009 p866**
66. Stamos C, Koutsopoulos VA, Pitiava D, Fiska A, Nikolettos N, Sivridis E, Manolas K, **Koukourakis M**, Giatromanolaki A. Tumour angiogenesis and hypoxia in breast carcinomas: correlaton with node metastasis and prognosis. **22nd European Congress of Pathology. 4-9 September 2009, Florence, Italy.**
67. Sivridis E, Stamos C, Fiska A, Nikolettos N, Koutsopoulos VA, Koukourakis M, Giatromanolaki A. c-erbB-2 and the tripple-state in early breast carcinomas. **22nd European Congress of Pathology. 4-9 September 2009, Florence, Italy.**
68. Vassiliades N, Tsirtsidis V, Giatromanolaki A, **Koukourakis MI**, Costntinidis TC, Sivridis E. Importance of regional cancer registry in Greece. Publich health and Health Care in Greece and Bulgaria: The challenge of the cross-border collaboration. **Alexandroupolis 8-10 May, 2009.**
69. Takos D, Milioudis S, Mavropoulou S, Nasos P, **Koukourakis M**, Kakolyris S, Kalogeris K. Lymphoepithelioma – like carcinoma of urinary bladder. **1st Athenian EuroAmerican Congress of Urology. Athens, 15-18 June, 2006**
70. Giatromanolaki A, Charalambidis Ch, Koukourakis MI, Sivridis E. PKDR expression in endometrial cancer cells relate to HIF1a/VEGF factors. **2dn Intercongress of the European Society of Pathology, Ioannina, May 24-27, 2006**
71. Giatromanolaki A, Charalambidis Ch, Koukourakis MI, Sivridis E. Loss of FOXP1 is a common event in early endometrial cancer: relationship with estrogen receptors and HIF1a expression. **2dn Intercongress of the European Society of Pathology, Ioannina, May 24-27, 2006**
72. Kapsoritakis A, Koukourakis MI, Sfiridaki A, Kouroumalis EA. Vascular Endothelial Growth Factor Plasma levels in patients wit inflammatory bowel disease. **Falk Symposium 123. VI International symposium on inflammatory bowel diseaseInstambul September 3-5, 2001 Abstr 62**
73. Giatromanolaki A, Stathopoulos G, Rigatos S, **KOUKOURAKIS MI**, Sivridis E. Angiogenesis, bcl2/bax and p53 expression in locally advanced gastric cancer treated with paclitaxel and carboplatin chemotherapy. **9th International congress on anti cancer treatment. February 1999, Paris.**
74. **KOUKOURAKIS MI** et al. Stealth liposoma doxorubicin combination with radiotherapy for non-small cell lung cancer. A phase I dose escalation study. **9th International congress on anti-cancer treatment. February 1999, Paris.**
75. Giatromanolaki A, **KOUKOURAKIS MI**, Kakolyris S, et al. VEGF , p53 and angiogenesis in non small cell lung cancer. **3rd International Congress on Lung Cancer , Rhodes, 1998**
76. **KOUKOURAKIS MI**, Giatromanolaki A, Guddo F, Kaklamanis L et al. Episialin and c-erbB-2 challenge host immune response by HLA-class I expression in non small cell lung cancer. **3rd International Congress on Lung Cancer , Rhodes, 1998**
77. Varveris H, Haldeopoulos D, Mazonakis M, **KOUKOURAKIS M**, Tsiftsis D. Concurrent chemoradiotherapy with external beam irradiation for unresectable cancer of the colon and rectum. Analysis of 32 cases. **8th European Interuniversity Symposium. Colorectal cancers. Naoussa 26-30 August, 1998**
78. **KOUKOURAKIS M**, SKarlatos J, Kosma L, Zambatis C, Pissakas G, Giatromanolaki A, Beroukas K, Yannakakis D. Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. **8th European Interuniversity Symposium. Colorectal cancers. Naoussa 26-30 August, 1998**
79. **KOUKOURAKIS MI**, Kakolyris S, Kouroussis C, Vrahasotakis N, Haldeopoulos D, Varveris C, Tsiftsis D, Georgoulis V. Hyperfractionated biomodulated chemo-radiotherapy with Interferon-a, leucovorin and 5-fluorouracil for postoperative stage C2 rectal cancer. A feasibility study. **8th European Interuniversity Symposium. Colorectal cancers. Naoussa 26-30 August, 1998**
80. **KOUKOURAKIS MI**, Giatromanolaki A, Skarlatos J, Kosma L, Apostolikas N, Beroukas K. bcl-2 anti-apoptotic oncoprotein suppresses angiogenesis in non-small cell lung cancer. Implications in resistance to photo-dynamic therapy ? **In «SPIE. Proceedings Series», Vol 3423, pp 432-435; 1997**
81. Giatromanolaki A, **KOUKOURAKIS M** et al., Interleukin 4 receptor expression and metastasis in human breast cancer. Recent advances in diagnostic imaging and supportive care in Oncology. **7th European Interuniversity symposium organized by the Aristoteles Institute. 1997**

82. Giatromanolaki A, KOUKOURAKIS M et al. Angiogenesis is a significant prognostic marker in operable non small cell lung cancer. Recent advances in diagnostic imaging and supportive care in Oncology. **7th European Interuniversity symposium organized by the Aristoteles Institute. 1997**
83. Ververis C, Haldeoploulos D, KOUKOURAKIS M et al. External beam irradiation for unresectable cancer of the colon and rectum. Recent advances in diagnostic imaging and supportive care in Oncology. **7th European Interuniversity symposium organized by the Aristoteles Institute. 1997**
84. KOUKOURAKIS M et al. Hypofractionated radiotherapy combined with 5FU in the treatment of locally advanced breast carcinoma. Recent advances in diagnostic imaging and supportive care in Oncology. **7th European Interuniversity symposium organized by the Aristoteles Institute. 1997**
85. Pissakas G, Sotiropoulou A, Varveris Ch, Kouvaris M, KOUKOURAKIS M, Kosma L. Palliation of advanced pelvic malignancies after irradiation with multiple daily fraction. **1st International Congress on cancer Pain relief and paliative care. November 1994, Athens**
86. Pissakas G, Varveris Ch, Sotiropoulou A, KOUKOURAKIS M et al. Prophylactic versus symptomatic irradiation of brain metastases from small cell carcinoma of the lung. **1st International Congress on cancer Pain relief and paliative care. November 1994, Athens.**
87. KOUKOURAKIS M, Giatromanolaki A, Gatter KC, Harris AL. Bcl-2 and c- erbB-2 gene products are involved in the regulation of thymidine phosphorylase (PD-ECGF) angiogenic activity in NSCLC. **2nd International Congress on Lung Cancer , Iraklion - Crete, 9-13 Nov 1996 Best oral presentation Award**
88. Giatromanolaki A, KOUKOURAKIS M, O;Byrne K, Gatter KC, Kittas C, Veslemes M, Iordanoglou I. Prognostic role of EGFR and c-erbB-2 oncogene overexpression in NSCLC. **2nd International Congress on Lung Cancer , Iraklion - Crete, 9-13 Nov 1996**
89. KOUKOURAKIS MI, Skarlatos J, Kosma L, Giatromanolaki A, Damilakis J, Yannakakis D. Overall treatment time: a major factor influencing the results of radiotherapy for NSCLC. **2nd International Congress on Lung Cancer , Iraklion - Crete, 9-13 Nov 1996**
90. Koukouraki S, Giatromanolaki A, Damilakis J, Skarlatos J, Karkavitsas N, Kourakos C, Georgoulas V, Kourousis H, KOUKOURAKIS M. Tc99m sestamibi radionuclide excretion rate in lung cancer: possible implications in predicting multidrug resistance. **2nd International Congress on Lung Cancer , Iraklion - Crete, 9-13 Nov 1996**
91. Giatromanolaki A, KOUKOURAKIS M, et al. Plasma cell, macrophage and tumour neoangiogenesis in NSCLC. **2nd International Congress on Lung Cancer , Iraklion - Crete, 9-13 Nov 1996**
92. KJ O'Byrne, M. KOUKOURAKIS, A Giatromanolaki et al. Tumour angiogenesis in non small cell lung cancer. **British Association for Cancer Research, Joint Winter Meeting, December 1995**
93. KOUKOURAKIS M, Saunders M, AL. Harris. A pilot study of cyclophosphamide methotrexate and infusional 5 fluorouracil for metastatic breast cancer. **Imperial Cancer Research Fund , Annual Coloquium, Worick, UK, March 1995.**
94. KJ O'Byrne, C Thompson, V Macauley, M KOUKOURAKIS, SM Wilner, TS Ganesan, DC Talbot, AL Harris. Bryostatins in metastatic malignant melanoma. **Irish Association for Cancer Research, 33rd Annual Scientific Meeting, Limerick, April 1996**
95. MI KOUKOURAKIS, KJ O'Byrne, MP Saunders, R Isaaks, VM Macauley, S Varcoe, TS ganesan, AL Harris, DC talbot. A phase I/II study of cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. **Irish Association for Cancer Research, 33rd Annual Scientific Meeting, Limerick, April 1996**
96. KJ O'Byrne, MI KOUKOURAKIS, A Giatromanolaki, R Whitehouse, DC Talbot, KC Gatter, Al Harris. Bcl-2, c-erbB-2 and tumour angiogenesis in non-small cell lung cancer, **Irish Association for Cancer Research, 33rd Annual Scientific Meeting, Limerick, April 1996**
97. KJ O'Byrne, A Giatromanolaki, M KOUKOURAKIS, M Comley, RM Whitehouse, DC Talbot, KC Gatter, AL Harris. PD-ECGF expression correlates with tumour angiogenesis and prognosis in NSCLC. **British Association for Cancer Research, Spring Joint Meeting, March 1996**
98. MI KOUKOURAKIS, KJ O'Byrne, MP Saunders, R. Isaaks, VM Macauley, S. Varkoe, TS Ganesan, AL Haris, DC Talbot. Cyclophosphamide, Methotrexate and 5-fluorouracil (Infusional CMF) in metastatic breast cancer. **British Association for Cancer Research, Spring Joint Meeting, March 1996**